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Summary  
 
With an annual mortality of around a million people, most of whom are children, malaria 
remains a major health hazard in our times. Amongst the drugs used to treat malaria, 
compounds such as chloroquine (CQ) and quinine (QN) are no longer the first line 
antimalarials in use because of the spread of drug resistant Plasmodium falciparum, in 
particular that of the chloroquine resistant (CQR) strains.  
 
Central to CQR malaria is the Plasmodium falciparum chloroquine transporter (PfCRT), a 
trans-membrane protein located in the digestive vacuolar membrane of the parasite. It has been 
shown in the past that mutations in this protein are linked to an enhanced efflux of CQ from 
the digestive vacuole, which is the basis of CQR in P. falciparum. As part of this study, 
PfCRT was expressed in oocytes of Xenopus laevis, in order to understand the relationship 
between mutant pfcrt and transport of quinoline drugs. A number of naturally occurring and 
lab-constructed pfcrt mutants were expressed in oocytes, and transport measured for CQ, QN 
and its stereoisomer quinidine (QD). The data obtained showed that apart from being a carrier 
for CQ, mutant PfCRT exhibited saturable and verapamil-sensitive uptake of QN and QD, 
suggesting that PfCRT is a carrier for QN and QD as well. Using polymorphic pfcrt alleles, it 
was observed that mutations in pfcrt can influence the apparent Michaelis-Menten constant for 
CQ. While all mutant pfcrt alleles showed uptake of CQ albeit with differences, only the Dd2 
and GB4 alleles showed transport for QN and QD, indicating that pfcrt mutations may also 
influence the substrate specificity. Mutants generated for the Ecu1110 alleles showed that only 
three mutations can suffice for CQ transport. Amino acid substitution in the Dd2 allele 
revealed a role for residue 326 in quinoline substrate selectivity. Taken together, the data argue 
in favour of a model where PfCRT acts as a carrier for quinolines such as CQ and QN, whose 
kinetic parameters are dependent on the actual combination of mutant residues present.  
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Zusammenfassung 
 
Mit einer jährlichen Sterblichkeit von rund einer Million Menschen, von denen die meisten 
Kinder sind, bleibt Malaria eine der bedeutendsten Infektionskrankheiten unserer Zeit. Unter 
den Medikamenten die zur Bekämpfung von Malaria eingesetzt werden sind Chloroquin (CQ) 
und Chinin (QN) nicht mehr die erste Wahl. Der Grund dafür ist die sich immer weiter 
ausbreitender Resistenz von Plasmodium falciparum gegen antimalaria Medikamente, 
insbesondere gegen CQ. 
 
Die Zentrale Rolle bei der CQ Resistenz spielt der Plasmodium falciparum Chloroquin 
resistance transporter (PfCRT), ein in der Nahrungsvakuole des Parasiten lokalisiertes 
transmembranes Protein. Es wurde gezeigt, dass Mutationen innerhalb dieses Proteins mit 
einem erhöhten Efflux von CQ aus der Nahrungsvakuole einhergehen. Um die 
Zusammenhänge zwischen mutiertem pfcrt und dem Transport von Chinolinen zu verstehen, 
wurde PfCRT in Oozyten von Xenopus laevis exprimiert. Es wurden natürlich vorkommende 
sowie im Labor hergestellte Varianten von pfcrt in Oozyten exprimiert, anschließend wurde 
der Transport von CQ, QN und seines Isomers Quinidine (QD) gemessen. Die erhaltenen 
Daten zeigen, dass mutierte PfCRT Varianten außer CQ auch QN und QD transportieren. Es 
konnte auch beobachtet werden, dass Mutationen in PfCRT auch einen Einfluss auf die 
Michaelis-Menten Konstante für CQ haben. Während alle mutierten PfCRT Allele, wenn auch 
mit Unterschieden, Aufnahme von CQ zeigten, war nur im Fall von Dd2 and GB4 Allelen 
Transport von QN und QD zu beobachten, was darauf hindeutet, dass Mutationen in PfCRT 
auch einen Einfluss auf die Substratspezifität haben könnten. Versuche mit Ecu1110 Mutanten 
zeigen, dass nur drei Mutationen für den CQ Transport ausreichend sind. Die Ersetzung der 
Aminosäure an Position 326 im Dd2 Allel bewirkt eine Substratselektivität der Chinoline. 
Zusammenfassend sprechen die Daten für ein Modell, in dem PfCRT als Transporter für 
Chinoline wie CQ und QD fungiert, deren kinetische Parameter von der jeweiligen 
Kombination der mutierten Aminosäuren abhängen. 
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1  Introduction 
 
1.1   Malaria 
1.1.1  Global impact 
 
In the entire history of mankind, humanity has suffered much from diseases and the pain they 
inflict. But few maladies could be blamed for the scale of suffering and mortality that malaria 
has unleashed upon us. In an age where some diseases, which once meant certain death, have 
not only become treatable but curable, malaria presents us with a grim challenge. Of the entire 
world population, it is estimated that 2.37 billion live in areas of any risk of 
Plasmodium falciparum transmission – in Africa, South America, South asia and South east 
asia (Guerra et al., 2008). Fig 1.1 shows the distribution of P. falciparum malaria risk across 
the world. As for the actual number of cases pertaining to malaria, the World health 
orgnization has reported that an estimated 243 (range 190-311) million cases of malaria 
occurred in 2008, of which about 863,000 (range 708-1003 thousand) cases were lethal. 85 % 
of these deaths occurred in children under 5 years of age. Malaria accounted for 20% of all 
childhood deaths that occurred in Africa, where it is believed that a child dies every 45 
seconds of this disease (WHO, 2009). But the burden of malaria is not limited to mortality 
alone. It has a detrimental economic effect in areas of incidence; estimations made in the past 
suggested that the annual gross national product (GNP) grew 2% less in countries where 
malaria is endemic when compared to countries with similar economic background but 
without a major malaria burden (Chima et al., 2003, Sachs & Malaney, 2002). 
 
Fig 1.1: Global distribution of Plasmodium falciparum malaria risk (Guerra et al., 2008) 
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1.1.2  Origin and history  
 
The description of what were most certainly cases of malaria have been found in 
Mesopotamian clay tablets from 2000 BCE, Egyptian papyri from 1570 BCE and hindu texts 
from the 6th century BCE (Cox, 2010). Hippocrates observed that “tertian” malaria fevers 
were more severe than “quartan” fevers. The world malaria is derived from the latin “Malus 
Aria” meaning bad air, because malarial fevers were associated with swampy marshes in italy 
where the disease was observed (Haldar et al., 2007). For a large part of recorded history, 
miasmas arising from marshes were seen as the cause of malaria. This belief was first 
questioned when scientists such as Louis Pasteur and Robert Koch showed that disease 
aetiology can be linked to micro-organisms. The then new theories proposed two routes of 
transmission - either through inhalation i.e. air borne or through contaminated water. In fact, 
Corrado Thomasi-Crudelli and Theodor Klebs even claimed to have identified Bacillus 
malariae from the Pontine marshes. Charles Laveran questioned this and followed his 
observation that a pigment appeared to grow and eventually fill the corpuscles of malaria 
patients. His perseverance led to the discovey of the malaria parasite in 1880. The next 
breakthrough in understanding causative agents behind malaria came in 1987 when Ronald 
Ross showed that female Anopheles mosquitoes act as vectors for transmission (Cox, 2010).  
 
The malaria parasite is actually a broad term for what are different species of the genus 
Plasmodium. They belong to the Phylum-Apicomplexa; Class-Sporozoa, Order-Coccidia, 
Suborder-Haemosporidiae, Family-Plasmodiidae. The genus Plasmodium contains as many as 
120 species, of which only five infect humans. Four of these are P. vivax, P. malariae, 
P. ovale, and P. falciparum (Greenwood et al., 2008). The fifth one, P. knowlesi,  infects the 
long-tailed macaques Macaca fascicularis, but there has been evidence in the recent past that 
it can infect humans too, especially in Malaysia (Singh et al., 2004). Apart from humans, 
Plasmodium species infect a many reptiles, birds and mammals. For instance, Plasmodium 
berghei is a mouse malaria parasite whereas Plasmodium yoelli yoelli causes malaria in 
chicken. Of the human malaria parasites, almost 80% of all malaria cases in Africa are caused 
by P. falciparum, whereas P. vivax accounts for 95% of malaria cases in Asia (Carter & 
Mendis, 2002). P. vivax is highly disabling although not as deadly as P. falciparum. 
Hypnozoites of P. vivax and P. ovale can survive for years in the liver. P. malariae can 
remain for a long period of time as an asymptomatic infection blood stage infection, even if it 
does not form hypnozoites (Greenwood et al., 2008).  
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It is believed that the malaria parasite evolved from a free-living protozoan ancestor which 
had chloroplasts (Wilson & Williamson, 1997). Around 200 million years ago, when early 
Dipterans appeared, these adapted to a life inside the gut of aquatic insect larvae. Some of 
these parasites got adapted to a life-cycle divided between two separate hosts, facilitated by 
the blood-feeding habits of their insect hosts (Carter & Mendis, 2002). Human malaria 
parasites alternatively grow in humans and their mosquito hosts i.e. the female Anopheles 
mosquitoes. Of 400 species Anopheles species found across the world, 60 have been 
identified as vectors for malaria parasites under natural conditions and of these 30 are of 
major importance (Tuteja, 2007). In Africa, where malaria mortality is highest, 
Anopheles gambiae and Anopheles funestus act as the main vectors.  
 
1.1.3  Clinical manifestations 
 
Symptoms that characterize malaria are typically periodic fibrile episodes accompanied by 
chills, rigors and sweating. Other general symptoms such as body ache, nausea, weakness and 
prostration may also be observed. Splenomegaly is observed in untreated patients. 
P. falciparum infections are the deadliest of the human malaria parasites and is life 
threatening if undiagnosed and untreated. P.falciparum may be uncomplicated, and then 
progress to severe malaria. Severe malaria caused by P. falciparum infection causes 
dysfunctioning of kidneys, lungs and liver, and especially the sequestration of parasites in 
blood capillaries in the brain. P. falciparum malaria can progress  from uncompliciated to 
severe malaria within a few days and the disease outcome is fatal in 10-40% of all severe 
malaria cases (Schlitzer, 2007). A fatal nephritic syndrome can result due to chronic infection 
of P. malariae (Carter & Mendis, 2002).  
 
While malaria can certainly be a fatal disease, it is not necessarily so. A number of factors 
such as multiplication rate of the parasites, cytoadherence, invasion pathways, host immunity 
to the malaria parasite, age of the infected patient, genetic traits of the host, as well as other 
variables such as availability of and access to treatment can determine the course of 
development of malaria after an infectious bite by the mosquito vector (Miller et al., 2002). 
However, when it does develop, disease progression in malaria happens in various stages 
which in all last 6-10 hours. The first is a cold stage, where the patient feels cold and may 
shiver. It is followed by hot stage where fever develops, along with headache and vomiting. 
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Seizures are commonly observed in children at this stage. A sweating stage follows the hot 
stage and as its name suggests, the patient now sweats and feels tired, whereas the body 
temperature returns to normal. The periodicity of attacks depends on the actual Plasmodium 
species with which the patient is infected; every second day for P. falciparum, P. vivax and 
P. ovale (“tertian” parasites) and every third day for P. malariae (“quartan” parasites). The 
intervals at which symptoms occur can be correlated with the release of TNF-α from 
macrophages as a response to rupturing erythrocytes (Kwiatkowski et al., 1989). On the other 
hand, parasite egress from erythrocytes is often unsynchronized in case of P. falciparum, 
which leads to a persistent fever or fibril paraoxyms (Rasti et al., 2004). 
 
Severe malaria is a condition described by a P. falciparum infection which eventually leads to 
organ failure and metabolic disequilibrium. Severe anaemia, coma and respiratory distress 
constitute the clinical spectrum of malaria in African children (Marsh et al., 1995). Anaemia 
is defined by a 5g/L of haemoglobin in a patient (Warrell, 1989b), and is an outcome of 
erythrocyte destruction and suppression of erythropoesis (Clark & Chaudhri, 1988). Coma, 
which occurs in cerebral malaria, is the effect of infecting erythrocytes adhering to the brain 
microvasculature. Such cytoadherence is the product of the P. falciparum erythrocyte 
membrane protein 1 (PfEMP1) family of proteins (Baruch et al., 1995, Kirchgatter et al., 
2005, Warrell, 1989a). Alternately, lactic acidosis can be a cause of severe malaria (English et 
al., 1996). Respiratory distress is most likely the result of lowered oxygen delivery caused by 
severe anemia and tissue perfusion impaired by parasite sequestration. It can thus be argued 
that the clinical outcome of malaria is determined by a number of factors and is in itself a 
complex process.  
 
1.1.4  Life cycle 
 
The life cycle of malaria parasites consists of a mosquito stage and two human stages – one in 
the liver and the other in blood. Female Anopheles mosquitoes feeding on humans inject 
around 100 sporozoites during their blood meal (Medica & Sinnis, 2005, Jin et al., 2007). 
They stay at the site of infection about 30 minutes, where a majority remain confined while 
some are released in the peripheral circulation. Those sporozoites which do make it into the 
blood stream reach the liver where they infect hepatocytes (Amino et al., 2008, Vanderberg & 
Frevert, 2004, Yamauchi et al., 2007).  
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Fig 1.2: Life cycle of the malaria parasite (Greenwood et al., 2008)  
 
In order to gain access to hepatocytes so as to be able to infect them, sporozoites need to cross 
liver sinusoids which are composed of fenestrated endothelial cells and Kupffer cells. Since 
the enthothelial cell fenestrae are too small for the sporozoite to cross them, they have to 
migrate through the sinusoidal cells to access the liver parenchyma. Hepatocyte invasion by 
sporozoites requires proteins such as the circumsporozoite protein and thrombospondin-
related adhesions, which contain a thrombospondin domain (Ejigiri & Sinnis, 2009). These 
domains interact with their host – cell receptors such as heparin sulphate proteoglycans 
present on the hepatocyte surface  (Frevert et al., 1993). P. falciparum sporozoites undergo 
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asexual replication in the hepatocyte, culminating in the formation of thousands of 
merozoites. This replication cycle is also called Exo-erythrocytic sporogeny, and a single 
infected hepatocyte may contain upto 3000 merozoites (Ejigiri & Sinnis, 2009). Merozoites 
eventually rupture the host hepatocytes and subsequently invade erythrocytes. The liver stage 
of Plasmodium infection, during which merozoites are formed in hepatocytes, is 
asymptomatic, lasts around 6 days and is also termed the prepatent period (Greenwood et al., 
2008). The exact duration of the prepatent phase, however, differs between Plasmodium 
species. It lasts between 8-27 days for P. vivax, 9-17 days for. P. ovale and 15-30 days for 
P. malariae. With P. vivax and P. ovale infections, some of the sporozoites that have invaded 
hepatocytes can form hypnozoites, which develop into exo-erythrocytic schizonts at a later 
time point. The signal that triggers the conversion of hypnozoites, however, is unknown 
(Cogswell, 1992).  
 
Within minutes of their release from rupturing hepatocytes, merozoites invade erythrocytes 
where they begin the second cycle of asexual replication within the infected host. The 
invasion process is a highly co-ordinated event and occurs in a step-wise manner. The initial 
contact between the host cell and the merozoite is a low affinity interaction (Bannister & 
Dluzewski, 1990), involving host cell surface receptors and proteins on the merozoite surface 
such as the associated protein complex and MSP-1 (Chitnis & Blackman, 2000). Following 
the initial attachment, the parasite undergoes a reorientation in order to juxtapose its apical 
end with the erythrocyte membrane (Cowman & Crabb, 2006). Apical membrane antigen-1 
(AMA1) is a protein that gets translocated to the merozoite surface before invasion begins and 
is required for the apical reorientation, although not for the initial interaction between the 
merozoite and the erythrocyte (Mitchell et al., 2004). The reorientation allows for the 
formation for a tight junction between the parasite and host surface, which moves from the 
apical to the posterior end of the invading merozoite through a series of complex events 
which involve the actin-myosin motor of the invading merozoite (Keeley & Soldati, 2004). 
Micronemes, which are organells located apically in merozoite, release a serine protease 
named SUB2 which cleaves off proteins coating the merozoite surface (Harris et al., 2005). 
The invading merozoite pushes itself into the erythrocyte and forms a parasitophorous 
vacuole that envelopes the parasite. The invasion process forms a major target for anti-
malarial vaccine development, and blocking this process through antibodies against MSP-1 
and AMA-1 is being actively pursued (Matuschewski & Mueller, 2007).  
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Once inside the erythrocyte, the parasite undergoes a second cycle of asexual replication, 
marked by a series of intraerythrocytic stages of development namely the ring, the trophozoite 
and the schizont stage (Bannister et al., 2000). The ring stage is marked by low metabolic 
activity and only ring stage P. falciparum parasites are found circulating in the bloodstream of 
the infected host, as in the later stages the parasite modifies the erythrocyte surface leading to 
sequestration of the infected erythrocytes (Chen et al., 2000, Baruch, 1999). In contrast to the 
ring stage, the trophozoite stage is metabolically highly active, as marked by high rates of 
glycolysis and haemoglobin proteolysis (Miller et al., 2002). The trophozoite stage is 
followed by multiple rounds of cell division albeit without cytokinesis, leading to the 
formation of schizonts. Erythrocytes rupture following the schizont stage, and each individual 
schizont can produce 8-24 merozoites which are then released into the blood stream from the 
lysed erythrocytes. The release of merozoites coincides with the spiking of fever observed in 
malaria patients. Since merozoite release is synchronous and they are released approximately 
at the same of the day, the resulting fever is also periodic (Tuteja, 2007). The erythrocytic 
stage of Plasmodium infection is thus a symptomatic stage. The duration of a single 
erythrocytic cycle differs among various Plasmodium species, with the time taken to complete 
one such cycle being 48 hours for P. falciparum and P. vivax and 72 hours for P. malariae.  
 
A small number of merozoites that invade erythrocytes do not undergo asexual replication 
culminating in schizont formation, but instead differentiate into male and female gametocytes 
(Bruce et al., 1990). The factors triggering gametoyctogenesis are not clearly understood, and 
may include interplay between a number of host factors as well as parasite signalling 
pathways (Baker, 2010). In case of P. falciparum, hepatic merozoites cannot transform into 
gametocytes, although this has been observed for other species (Talman et al., 2004). 
Gametocytogenesis involves five stages; stage I-IV gametocytes get sequestered in the bone 
marrow and spleen whereas stage-V gametocytes are released into peripheral circulation  
(Talman et al., 2004) and get ingested into the midgut of a a mosquito biting an infected host. 
Within 10 minutes after their entry into the midgut, male gametes undergo three rounds of 
DNA replication, followed by exflagellation, thus producing motile microgametes. A single 
microgamete is composed of a plasma membrane enclosing an axoneme and a nucleus. 
Exflagellation involves binding of the newly formed microgametes to erythrocytes ingested as 
part of the blood meal forming a cluster known as the exflagellation center. Individual motile 
microgametes are subsequently released to seek out and fertilize macrogametes. Fertilization 
of non-motile macrogametes by motile microgametes forms a zygote, which transforms into a 
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motile ookinete (Eksi et al., 2006). Ookinetes are mature diploid zygotes, and peak ookinete 
production for P. falciparum takes place 24-30 after the bloodmeal (Beier, 1998). Ookinetes 
are motile and traverse the epithelial layer lining the mosquito midgut (Siden-Kiamos & 
Louis, 2004), after which they get arrested in the basal lamina and transform into oocysts. 
Sporoblasts are formed from oocytes after several rounds of mitotic division. Budding of 
sporozoites from sporoblasts takes place 10-14 days after the blood meal. Sporozoite egress 
from oocytes through proteolytic activity and enter the mosquito haemolymph. Sporozoites 
passing the salivary glands of the mosquito adhere to the basal lamina in salivary glands, 
invade and exit acinar cells to eventually accumulate in the salivary duct. The arrival of 
sporozoites in the salivary duct completes the mosquito vector stage of the Plasmodium life 
cycle (Matuschewski, 2006). When such a mosquito vector bites a human host, some 
sporozoites get injected into the human host, thus beginning another round of the Plasmodium 
life cycle.  
 
1.1.5  Remodelling of P. falciparum infected erythrocytes  
 
The host erythrocyte invaded by a P. falciparum parasite undergoes extensive remodelling, 
such that new parasite-induced structures appear on the erythrocyte surface as well as within 
the host cell cytoplasm (Cooke et al., 2004b). Such remodelling is not found in case of 
infection with the other human malaria parasites (Miller et al., 2002). These modifications 
contribute to the virulence and pathogenecity of P. falciparum (Cooke et al., 2004a). They 
include the appearance of knob-like extrusions on the erythrocyte surface, establishment of a 
membranous network of parasite origin called the Maurer’s clefts as well as new permeation 
pathways (NPPs).  
 
It has been known for a long time that P. falciparum infected red blood cells (PfiRBCs) have 
knob-like structures on their surface (Luse & Miller, 1971). These are observed in the 
trophozoite stage of the parasite life cycle, and can be seen in EM as electro-dense punctuate 
protrusions underlying the erythrocyte membrane, which are 30-40 nm in height and 90 nm in 
diameter (Tilley & Hanssen, 2008, Tilley et al., 2008). At the molecular level, knobs are 
responsible for the cytoadherence property of PfiRBCs which plays an important part in 
sequestration of parasitized erythrocytes in the microvasculature, which in turn has been 
implicated in the fatal nature of P. falciparum malaria, as manifested by cerebral & placental 
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malaria and rossetting & clumping of PfiRBCS (Miller et al., 2002). Knobs are associated 
with proteins of parasite origin such as the Knob associated histidine rich protein 1 
(PfKARHP1) and the Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1). 
Knobs also modify physical properties of the host cell through their interaction with 
cytoskeletal components of erythrocytes such as spectrin, ankyrin and actin (Pei et al., 2005, 
Kilejian et al., 1991a, Kilejian et al., 1991b).  
 
PfEMP1 appears on the erythrocyte surface in the trophozoite stage of the parasite life cycle  
about 14-18 post merozoite invasion (Baruch et al., 1996) and plays a crucial role in the 
pathophysiology of P. falciparum malaria (Pasternak & Dzikowski, 2009). For instance, 
PfEMP1 is involved in pregnancy associated malaria as it binds chondroitin sulphate A 
present in the placental lining (Reeder et al., 2000, Viebig et al., 2007). It also mediates the 
rosetting of uninfected erythrocytes to PfiRBCs (Rowe et al., 1997). PfEMP1 can bind to host 
receptors such as intracellular adhesion molecule-1 (Berendt et al., 1989, Ochola et al., 2010), 
CD36 (Barnwell et al., 1989, Ockenhouse et al., 1989), P-selectin (Ho et al., 1998), 
PCAM/CD31 (Heddini et al., 2001), and the interaction between PfEMP1 and its host 
receptor also influences the disease outcome (Ochola et al., 2010). PfEMP1 is encoded by the 
var gene family, and 60 members of this family have been identified in P. falciparum. The 
parasite expresses only a single allele at a time, while maintaining other alleles in a 
transcriptionally silent state, and expresses different var alleles during its life cycle (Scherf et 
al., 2008). Erythrocytes are terminally differentiated, metabolically dead cells which lack 
subcellular organelles and a de-novo lipid/protein synthesis mechanism (Mohandas & Chasis, 
1993), and thus are an ideal hiding place for the parasite to shield itself from the host immune 
system. Why then, does the parasite take the risk of revealing its presence in infected 
erythrocytes by expressing adhesion molecules such as PfEMP1? A widely accepted view is 
that the sequestration of PfiRBCs in microvasculature allows infected erythrocytes to escape 
destruction in the spleen (Dondorp et al., 1999). Another hypothesis suggests that PfEMP1 
expression helps in illiciting an immune response to PfiRBCs, thereby controlling blood-stage 
pararasitaemia, which can otherwise rise to levels that threaten host survival (Saul, 1999).  
 
P. falciparum parasites possess components of the classical protein trafficking machinery 
found in eukaryotes such as the endoplasmic reticulum Sec61 translation complex (Couffin et 
al., 1998), a signal peptidase complex (Sharma et al., 2005), proteins required for vesicular 
transport (Adisa et al., 2002, Ayong et al., 2007) as well as a Golgi network (Struck et al., 
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2005). The parasite can therefore synthesis proteins and traffick them upto the 
parasitophorous vacuole membrane (PVM). Taking proteins beyond the PVM and expressing 
them at the host cell surface is complicated by the fact that erythrocytes lack subcellular 
organelles and a protein trafficking machinery (Mohandas & Chasis, 1993). Maurer’s clefts, 
which are parasite derived membranous structures comprising of one or more lamellae and 
bordered by a single membrane & an electron-dense coat (Aikawa, 1971, Atkinson & 
Aikawa, 1990, Atkinson et al., 1988), aid in the trafficking of parasite proteins to the host cell 
surface (Wickert et al., 2003). Named after Georg Mauer who first decribed them in 1900 
(Lanzer et al., 2006, Wickert & Krohne, 2007), Maurer’s clefts contain proteins such as  the 
skeletal binding protein-1 (Blisnick et al., 2000, Saridaki et al., 2009), ring exported protein-2 
(Spielmann et al., 2006) and members of protein families such as the subtelomeric variable 
open reading frames (Kaviratne et al., 2002, Przyborski et al., 2005) and repetitive intersped 
family (Khattab & Klinkert, 2006). Apart from a protein synthesis machinery, human 
erythrocytes also lack a de-novo lipid synthesis mechanism as well as a number of solutes 
required for parasite survival (Baumeister et al., 2006). The parasite is thus forced to uptake 
nutrients from the blood plasma. It achieves this through the induction of new permeability 
pathways (NPPs) in the host cell (Staines et al., 2007, Kirk & Saliba, 2007, Kirk et al., 1999, 
Decherf et al., 2004). NPPs are induced 12 to 15 hours after invasion, and dramatically 
increase erythrocyte permeability to low molecular solutes such as amino acids, sugars, 
nucleosides, vitamins, organic and inorganic ion (Saliba & Kirk, 2001). The molecular 
composition of NPPS, however, remains unclear. It has been proposed that they may consist 
of two kinds of channels – one present in small numbers and the other that is in lesser 
numbers but which is charge and size selective (Ginsburg & Stein, 2004).  
 
Fig 1.3: Remodelling of P. falciparum infected erythrocytes (Tilley et al., 2008b) 
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1.2  Chemotherapy for malaria  
 
Chemotherapeutic agents used to treat malaria can be classified as per the stage of  the 
Plasmodium life cycle they act upon. Blood schizonticides act on the symptomatic asexual 
intraerythrocytic stage of Plasmodium development, and constitute the major class of 
antimalarial in use – more so since they help in releaving malaria symptoms. Tissue 
schizonticides, on the other hand, kill hepatic schizonts and therefore are prophylactic in 
nature as these prevent Plasmodium parasites from progressing to the blood stages. As against 
tissue schizonticides, hypnozoiticides kill the hypnozoites of P. vivax and P. ovale and are 
used to prevent a relapse of malaria. Hypnozoiticides may be used in combination with tissue 
schizonticides to cure the infection and simultaneously prevent relapse in P. vivax or P. ovale 
malaria (Kumar et al., 2003). Gametocytocides kill the sexual forms of the malaria parasite, 
thus blocking parasite transmission from the human to host to the mosquito vector (Schlitzer, 
2007). Since P. falciparum accounts for the lion’s share in malaria mortality, the main focus 
of malaria chemotherapy is to cure P. falciparum infections. This can be achieved with 
compounds that are classified as antifolates, antibiotics, inhibitors of the parasite respiratory 
chain, artemisinin derivatives, aminoquinolines and arylaminoalcohols.  
 
1.2.1  Antifolates  
 
Antifolates include the drugs sulfadoxine, dapsone, pyrimethamine and proguanil. The term 
antifolate describes that these compounds target the folic acid metabolism. Folic acid is 
required for DNA synthesis and is essential for the malaria parasite (Metz, 2007). The 
biosynthesis of tetrahydrofolate, the biologically active form of folic acid, involves enzymes 
such as the dihydropteroate synthase (DHPS) and the dihydrofolate reductase (DHFR). 
Sulfadoxine is a sulphonamide that acts as a competitive inhibitor of DHPS, whereas dapsone 
is a sulfone that acts as a pseudosubstrate for this enzyme. Pyrimethamine and proguanil, 
which is the active metabolite of cycloguanil, inhibit DHFR (Nzila, 2006). DHSP inhibitors 
have a weak antimalarial activity, and are not used alone but rather with DHFR inhibitors as 
the two types of compounds have a synergistic effect when used together. Fansidar® is the 
commercially available combination of sulfadoxine/pyrimethamine (S/P), whereas 
dapsone/chlroproguanil (D/C) combination is  sold as LapDap® (Schlitzer, 2007). Resistance 
to antifolates involves mutation in dhfr, the gene coding for DHFR. S/P was once used as a 
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first-line antimalarial (Baird, 2005), but the spread of resistant strains carrying dhfr mutations 
has more or less ended the use of S/P to treat P. falciparum infections. D/C is active against 
strains carrying triple mutations in dhfr, which are found in Africa, but not against the 
quadruple mutants found in Asia and South America (Wilairatana et al., 1997). 
 
1.2.2  Antibiotics 
 
Antibiotics such as doxycyclin, clindamycin and azithromycin have been reported to have 
antimalarial activity. They interact with and inhibit the protein synthesis machinery of the 
parasite mitochondrion or apicoplast (Vaidya, 2004, Goodman et al., 2007). One of the 
hallmarks of their mechanism of action is the so-called “delayed death phenotype”, whereby 
parasites are killed in the second cycle of intraerythrocytic replication (Dahl et al., 2006, 
Ramya et al., 2007). Consequently, time required for fever and parasite-clearance is higher for 
antibiotics than classical antimalarials (Lell & Kremsner, 2002). Antibiotics are therefore only 
used in combination with faster acting drugs such as quinine, artesunate or fosfidomycin. 
Doxycyclin is the most commonly used in combination with quinine or artesunate for the 
treatment of uncomplicated and severe malaria (Ashley & White, 2005). It may be replaced 
with clindamycin, which has a better safety profile in pregnant women and young children 
(Lell & Kremsner, 2002). Azithromycin is less effective than doxycyclin against 
P. falciparum malaria (Taylor et al., 2003), and has been used in trials in combination with 
dihydroartemisinine (Krudsood et al., 2002).  
 
1.2.3  Inhibitors of the respiratory chain 
 
Atovaquone is a hydroxynapthoquinone that breaks down the mitochondrial membrane 
potential in malaria parasites. Its mechanism of action at the molecular level involves binding 
to the ubiquinone binding site of the cytochrome bc1 complex in the parasite mitochondrion, 
thus blocking the movement of an iron-sulfur cluster protein that take part in mitochondrial 
electron transport (Korsinczky et al., 2000). Resistance against atovaquone is quick to emerge 
when it is used in monotherapy, because a single amino acid mutation in the Qo site alters the 
binding between atovaquone and the cytochrome bc1 complex by as much 1000 fold (Vaidya 
& Mather, 2000, Srivastava et al., 1999). It is therefore used in combination with proguanil 
Introduction 
 15
and sold under the brand name of Malarone®. Proguanil and atovaquone have a synergistic 
effect in combination; when atovaquone inhibits the mitochondrial electron transport, an 
alternative pathway involving ATP/ADP transporter get activated which is inhibited by 
proguanil (Painter et al., 2007, Painter et al., 2010). Malarone® is used as a prophylactic 
agent against P. falciparum malaria and in the treatment of uncomplicated malaria (Patel & 
Kain, 2005).  
 
1.2.4  Artemisinin derivatives 
 
Artemisinin is a sesquiterpene lactone that was first isolated from the extracts of the plant 
Artemisia annua in China in 1971 (Haynes & Vonwiller, 1994). Artemisinin has a very good 
antimalarial activity, as evidenced by mean IC50 values in the range of 12 to 20 nM for 
P. falciparum field isolates (Ramharter et al., 2002, Tanariya et al., 2000). It is, however, 
poorly soluble in water and oil which is why synthetic derivatives of artemisinin are used. 
These include artemether, artesunate and dihydroartemisinin (Schlitzer, 2007). Artemisinines 
reduce parasite biomass by upto 10,000 fold in a single asexual cycle of parasite replication 
and have a short plasma half-life of about an hour in humans making them the fastest acting 
antimalarials available (White, 1997, Dondorp et al., 2010). It is therefore no surprise that 
artemisinin compounds have been the drug of choice to treat P. falciparum malaria, especially 
cases of severe malaria, and more so since the global spread of chloroquine and S/P resistant 
malaria (Krishna et al., 2008). Combination of artemisinin derivatives with other partner 
drugs, also called Artemisinin combination therapy (ACT), is recommended by the WHO as 
the first line of treatment against P. falciparum infections (WHO, 2009). Artemether-
lumefantrine, artesunate-mefolquine, artesunate-amodiaquine, dihydroartemisinin-piperaquine 
as well as artesunate-pyronaridine are the combinations in use as ACTs (Eastman & Fidock, 
2009). It has been established that the key to the antimalarial activity of artemisinin 
compounds is an endoperoxide linkage, which gets cleaved by iron-II sources of the parasite. 
This cleavage results in carbon centered radicals which kill the malaria parasite (Schlitzer, 
2008). The exact cellular target of artemisinines remains unclear. While some claim that 
PfATP6, a calcium pump localized in the endoplasmic reticulum membrane, is inhibited by 
artemisinin derivatives (Eckstein-Ludwig et al., 2003), others have presented the digestive 
vacuole and the heme detoxification occuring in this parasite organelle as the targets (del Pilar 
Crespo et al., 2008, Pandey et al., 1999). While the molecular details of artemisinin mode of 
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action remain to be better established, it is widely accepted that the biggest threat facing 
global malaria control is potential therapeutic failure of ACTs. Clinically relevant resistance 
to artemisinines is yet to be reported from the field, but cases of decreases clinical efficiency 
and susceptibility have already been reported at the border of Cambodia and Thailand 
(Dondorp et al., 2010, O'Neill et al., 2010).  
 
1.2.5  Aminoquinolines and arylaminoalcohols 
 
Powdered bark of the chinchona tree (Cinchona pubescens) was reportedly the first ever 
chemotherapeutic agent used to treat malaria, and was found to contain quinine and quinidine. 
Efforts aimed at in vitro synthesis of quinine inadvertently led to the production of synthetic 
dyes, of which methylene blue was found to stain malaria parasites. Paul Ehlrich’s use of 
methylene blue as an antimalarial led to efforts aimed at modifying the chemical structure of 
methylene blue so as to yield novel compounds with antimalarial activity. Such endeavours 
eventually led to the synthesis of primaquine and resochin, with resochin being renamed as 
chloroquine through the course of history (Schlitzer, 2007).  
 
Chloroquine (CQ) and amodiaquine (AQ) belong to the family of 4-aminoquinolines, and 
currently the only 8-aminoquinoline in use is primaquine. CQ has been the most successful 
drug in the history of malaria treatment, as well as being one of the cheapest and safest 
antimalarials to have been used till date (Sanchez & Lanzer, 2000). Against these plus points, 
CQ has a narrow therapeutic index - the dose is 10 mg/kg; 20 mg/kg is toxic and 30 mg/kg 
can be lethal (Taylor & White, 2004). Widespread use of CQ, however, led to the emergence 
of CQ resistant P. falciparum which later spread across the world (Wellems & Plowe, 2001). 
This has resulted in the discontinuation of CQ as the preferred drug to treat P. falciparum 
malaria. AQ is very similar to CQ in its structure, except that it contains an aromatic ring in 
its side chain. Although structurally similar to CQ, AQ is effective against low-level CQ 
resistant strains of P. falciparum, but not against highly CQ resistant parasites (Sa et al., 
2009). AQ is in use mainly as a partner drug in artemisinin combination therapy (Eastman & 
Fidock, 2009). Both CQ and AQ act against the intraerythrocytic stage of the Plasmodium life 
cycle. In contrast to CQ and AQ, primaquine acts against the liver and sexual stages, and is 
especially used to treat P. vivax malaria (Hill et al., 2006).  
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Quinine, mefloquine, halofantrine and lumefantrine are classified as arylaminoalcohols 
(Schlitzer, 2008). Quinine is particularly used to treat severe malaria, mainly through 
intramuscular or intraperitoneal application. Its half-life of 8-12 hours, which means that the 
dosage has to be delivered 3 times daily (Okombo et al., 2011). Side effects can be severe, as 
it causes cardiac arrhythmia and insulin-induced hypoglycaemia (Taylor & White, 2004). 
This calls for careful monitoring of the patient when quinine is being administered, and due to 
such reasons quinine usage is not recommended except in cases of severe malaria.. 
Mefloquine is structurally similar to quinine and is used in combination with artesunate 
(Eastman & Fidock, 2009). It is also effective against most CQ resistant strains of P. 
falciparum (Ringwald et al., 1999), but can cause dose-related neuropsychiatric toxicity 
(AlKadi, 2007). Like mefloquine, halofantrine too is functional against CQ resistant strains, 
but the high risk of cardiac arrhythmia associated with halofantrine usage has meant that its 
use as an antimalarial is not recommended (Touze et al., 2002). Lumenfantrine, which is 
structurally similar to halofantrine albeit less potent, does not have the side effects of 
halofantrine. Lumefantrine is commercially available as a partner drug with artemether as 
Riamet® (Omari et al., 2004).  
 
1.2.6  New antimalarials undergoing development 
 
Emergence of resistance to existing antimalarial drug regimens not only compromises the 
fight against malaria, but also highlights the need to develop new compounds to be used to 
treat malaria. Different laboratories across the world are currently pursuing a number of 
compounds as potential antimalarial drugs. Some of these are AQ-13, tert-butyl isoquine and 
ferroquine which belong to the 4-aminoquinoline family of antimalarial drugs, and therefore 
are thought to share their mechanism of action with better known aminoquinolines such as 
chloroquine and amodiaquine (Schlitzer, 2008). A non-aminoquinoline drug which targets the 
parasite phospholipids metabolism is T3, and is also under development (Wengelnik et al., 
2002, Caldarelli et al., 2010). Apart from these, research on a guaianolide-endoperoxide 3 as 
an antimalarial agent has also been reported (Sun et al., 2010).  
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1.3  Quinolines - mechanism of action and resistance  
1.3.1  Haemoglobin degradation  
 
The capacity of the malaria parasite to synthesize amino acids de novo is limited (Sherman, 
1977). It complements this lack through the uptake of amino acids from its extracellular 
medium, as well as by deriving amino acids from haemoglobin degradation (Sherman et al., 
1969, McCormick, 1970). Hemoglobin, which is present at a concentration of 5 mM in the 
erythrocyte, accounts for 95% of total erythrocyte protein content (Francis et al., 1997). 
Inhibition of enzymes involved in haemoglobin degradation suggests that this process is 
essential for parasite survival (Rosenthal, 1995). Between 60-80% of the host cell 
haemoglobin is consumed by parasites during their intraerythrocytic proliferation (Rosenthal 
& Meshnick, 1996, Francis et al., 1997). Not only does this release amino acids require by the 
parasite, but it also creates space for its proliferation and generates osmolytes that prevent 
host cell lysis (Lew et al., 2003). Ingestion of the host cytoplasm occurs through endocytic 
structures called cytostomes, resulting in invaginations that get surrounded by the parasite 
plasma membrane and the parasitophorous vacuole membrane (Slomianny, 1990). There is 
some difference in opionion about the details of this process. Studies conducted in the past 
suggested that haemoglobin was delivered to the acidic digestive vacuole of the parasite in 
form of single membrane vesicles, after ingestion with a cytostome (Yayon et al., 1983). A 
more recent publication has put forward another explaination – that ring stage parasites engulf 
hemeglobin in a “big gulp” and haemoglobin uptake continues as the parasite matures, 
through the action of small cytostome-derived haemoglobin containing vesicles (Elliott et al., 
2008).  
 
Hemoglobin degradation occurs in the digestive vacuole (DV) of the parasite, although it has 
been observed that this process may already have started in vesicles bringing haemoglobin to 
the DV (Hempelmann et al., 2003). A number of proteases are involved in this process - the 
aspartic proteases Plasmepsin I, II, IV and a histo-aspartic protease along with the cystein 
proteases Falcipain – 1, 2, 2’ and 3. They convert large globin peptides to smaller fragments. 
The oligopeptides so formed are then converted by falcilysin and dipeptidylaminopeptidase –I 
(DRAP1) to dipeptides. Such dipeptides then get transported to the parasite cytoplasm where 
they are hydrolysed to individual amino acids (Ersmark et al., 2006). Heme is also released 
during haemoglobin degradation. Ferriprotoporphyrin IX (FPIX), which is the oxidized form 
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of heme, is highly toxic for the parasite as it damages biological membranes (Fitch, 1998). 
The parasite also lacks a hemoxygenase that is required for degrading FPIX (Pagola et al., 
2000). It therefore sequesters heme into inert hemozoin crystals which appear as refractile, 
dark brown crystals and have been known to biologists as the “malaria pigment” (Egan et al., 
2000, Fitch, 1998). Hemozoin crystals are made of ß-Hematin, which is a head to tail dimer of 
FPIX (Fitch, 1998, Roepe, 2009). Hemoglobin loaded endocytic vesicles are composed of two 
membranes which originate from the DV and the plasma membrane. During the maturation of 
these vesicles, their lumen gets acidified and one of the two membranes is degraded, releasing 
lipids in this process. The dimerization of FPIX requires an acidic environment, as well as 
unsaturated lipids such as linolic acid. Thus, both these conditions get fulfilled in the 
environment where haemoglobin degradation occurs, allowing the formation of hemozoin 
(Fitch, 2004). 
 
1.3.2 Mechanism of action of chloroquine and quinine 
 
Chloroquine (CQ) is a diprotic weak base that can diffuse through parasite membranes. This 
permits entry of CQ into the DV, which is the target of CQ (Yayon et al., 1984). The DV has 
an acidic pH (Kuhn et al., 2007) which causes diprotonation of CQ, and diprotonated CQ can 
no longer cross membranes with ease. CQ is thus “trapped” in the DV, which is where 
haemoglobin degradation takes place (Sanchez et al., 2007b). The mechanism of action of 
chloroquine (CQ) is thought to involve inhibition of heme polymerization to hemozoin (Fitch, 
2004). CQ can bind to FPIX, which prevents the dimerisation of FPIX to hemozoin crystals 
(Gligorijevic et al., 2006). CQ-FPIX complex also inhibits the maturation of endosomes 
containing haemoglobin, which leads to haemoglobin accumulation in immature endosomes 
(Fitch & Russell, 2006). Studies carried out using mouse erythrocytes infected with 
Plasmodium berghei have shown that parasites lose upto 80% of their ability to produce ß-
hematin in the presence of CQ. Furthermore, CQ also prevents the interaction of lipids 
involved in ß-hematin formation with FPIX, an effect which some have termed “lipid 
masking” (Fitch et al., 2003). The effect of CQ is therefore the accumulation of FPIX and the 
CQ-FPIX complex in the DV (Fitch et al., 2000). The presence of free FPIX damages 
membranes, either because CQ-FPIX complex directly destroys membranes or because its 
engenders a release of Ca2+ ions, which make vesicle membranes fuse too early with the DV, 
Introduction 
 20
thereby disrupting and orderly degradation of haemoglobin. Whatever the exact mechanism, 
the effects are lethal for the parasite (Fitch, 2004). 
 
  
                                                 Chloroquine                                        Quinine  
 
Fig 1.4: Chemical structures of chloroquine and quinine (Adapted from Schlitzer et al., 2008) 
 
 
Quinine is believed to share the mechanism of action of CQ to a large part, except another 
target for QN apart from FPIX is thought to exist (Fitch, 2004). A study in the past used EM 
to observe the morphology of infected erythrocytes treated with CQ and mefloquine, which is 
structurally similar to QN. The authors of this study proposed that while different quinolines 
appear to share the same targets, they led to morphologically different features in infected 
erythrocytes (Olliaro et al., 1989). Furthermore, the masking effect of CQ on lipids required 
for ß-hematin formation appears not to happen with QN (Fitch & Chou, 1997). Unlike CQ, 
QN also seems to inhibit the docking of haemoglobin loaded vesicles (Fitch, 2004). 
Mefloquine can directly bind to membranes and phospholipids whereas CQ itself did not 
show a high binding affinity in this study (Chevli & Fitch, 1982). QN, and its stereoisomer 
quinidine, can also form salt bridges with heme (de Villiers et al., 2008). 
 
1.3.3 Chloroquine and quinine resistance in P. falciparum 
 
The World Health Organization (WHO) defines antimalarial drug resistance as the ability of a 
parasite strain to survive and/or multiply despite the administration and adsorption of a drug 
given in doses equal to or higher than those usually recommended but within tolerance of the 
subject. The first cases of CQ resistance appeared in Thailand in 1957, and in Venezuela in 
1960. Until 2005, only the island of Hispaniola and coutnries in Central America, among the 
malaria endemic countriesof the world, remained free from CQ resistance (WHO, 2005). CQ 
resistant (CQR) strains of P. falciparum have originated independently from at least six 
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locations across the world – one in South East Asia which spread to Africa, one in Papua New 
Guinea, two in South America, one in Java and one in the Philippines (Wootton et al., 2002, 
Chen et al., 2003). In vitro resistance is measured through a right-ward shift in the IC50 
values, which correspond to a concentration which kills 50% of the parasitemia (White & 
Pongtavornpinyo, 2003). CQ IC50 values differ amongst isolates of geographically distinct 
origin. While susceptibility to CQ can be influenced by the parasite’s genetic background 
(Valderramos et al., 2010), pfcrt alleles from different geographical origins show variations in 
CQ IC50 when transfected in the same genetic background. Their response to verapamil, a 
chemosensitizer of CQ resistance, is also different (Sidhu et al., 2002, Henry et al., 2006, 
Lakshmanan et al., 2005). Apart from K76T, amino acid substitutions harboured by pfcrt 
from different geographical origins also change (Cooper et al., 2005, Chen et al., 2003, Sa et 
al., 2009). Withdrawal of CQ treatment in Malawi led to a reversal of CQR (Laufer et al., 
2006), although it was later shown that this was due to CQS parasites re-expanding rather 
than CQR parasites reverting to the CQS phenotype (Laufer et al., 2010). However, this does 
indicate that CQ resistance inflicts a fitness cost for the parasite. A recent study has shown 
that parasites harbouring the South American 7G8 pfcrt allele offer a selection advantage in 
competitive mosquito infections as compared to the wild-type parasites (Ecker et al., 2011). 
Thus, it is possible that fitness costs of CQ resistance may be linked to pfcrt alleles.  
 
One of the early reports on CQ resistance showed that altering pH of the DV can change the 
parasite susceptibility to CQ (Yayon et al., 1985). It was thought that CQR parasites may 
have a different digestive vacuolar pH (pHDV) than CQS parasites, which could led to CQ 
resistance. Some studies even backed this theory (Dzekunov et al., 2000, Ursos et al., 2000). 
However, it is known now that pHDV is around 5.2 units and is similar in both CQS and CQR 
parasites (Hayward et al., 2006, Kuhn et al., 2007). An alternative to this theory is that CQ 
accumulation is reduced in CQR than in CQS parasites, and that CQ resistance involves 
removal of the drug from its target. This has been backed by many studies (Krogstad et al., 
1992, Krogstad et al., 1987, Sanchez et al., 2003, Bray et al., 2006) and is now the consensus 
view. The involvement of ATP-binding cassete transporters, which mediate multidrug 
resistance in tumor cells(Baguley, 2010), was once implicated in CQR (Foote et al., 1990), 
although this has been found to be untrue (Wellems et al., 1990).  
 
Unlike CQ resistance, quinine (QN) resistance is not widespread, but found at low levels in 
Africa and South East Asia. Moreover, efficacy of QN has not changed much in malaria 
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endemic areas, which have otherwise become highly resistant to chloroquine (Okombo et al., 
2011). The mechanisms of CQ and QN resistance, however, do have something in common. 
Quantitative trait loci analyses have shown that pfcrt appears to be the single major genetic 
determinant of CQ resistance, whereas QN resistance involves the Plasmodium falciparum 
multidrug resistant transporter (PfMDR1) and the Plasmodium falciparum sodium proton 
exchanger (PfNHE1) in addition to PfCRT (Ferdig et al., 2004). pfmdr1 mutations and copy 
number have been linked to QN resistance, whereby a decrease in Pfmdr1 copy number 
increases QN susceptibility (Sidhu et al., 2006, Sidhu et al., 2005). PfNHE contains 3 
microsatellite regions, one of which contains DNNND repeats. The copy number of these 
repeats is in an inverse relationship with QN susceptibility (Ferdig et al., 2004). However, the 
interplay between different QN resistance markers is not fully understood.  
 
1.3.4  PfCRT 
 
Fig 1.5: Predicted topological model of PfCRT (Adapted from Sanchez et al., 2010) 
Transmembrane topology of PfCRT is shown, where blue coloured blocks indicate trans-membrane 
domains. Polymorphic residues are shown in red and numbered arrows indicate their numeric position 
in PfCRT sequence. Green arrows denote residues that may be phosphorylated. 
 
 
Using progenies of a cross between the chloroquine sensitive (CQS) HB3 strain and the 
chloroquine resistant (CQR) Dd2 strain, Wellems and co-workers identified a locus on 
chromosome 7 of the parasite that segregated with the CQR phenotype (Wellems et al., 
1990). This locus was found to contain the Plasmodium falciparum chloroquine resistance 
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transporter gene (pfcrt), which encodes a transmembrane protein that localizes to the DV 
membrane (Fidock et al., 2000). Transfection of mutant pfcrt into a wild-type background 
resulted in a moderate level of CQ resistance, thus confirming that pfcrt is central to CQR 
(Sidhu et al., 2002, Durand et al., 2001). Sequence analysis of pfcrt showed that CQR 
parasites possess a mutated copy of the gene as compared to the CQS strains. Among such 
mutations, the change of a lysine to threonine residue at position 76 (K76T), was found to be 
conserved (Fidock et al., 2000). When the reverse T76K replacement was introduced to CQR 
parasites, CQ and QN IC50 values to CQ dropped to CQS levels (Lakshmanan et al., 2005), 
suggesting that K76T is crucial for CQ resistance. The same report also proposed that the 
differences in verapamil reversibility of CQR, seen between South-American parasites such 
as 7G8 and South-East Asian parasites such as Dd2, are linked to the amino acid residues 
preceding K76T.  
 
It is known that CQR parasites accumulate less CQ than CQS parasites (Krogstad et al., 1992, 
Krogstad et al., 1987, Bray et al., 2006), and that most of the CQ within the parasite is 
contained in the DV (Bray et al., 2006). Because this organelle forms the target for CQ 
(Yayon et al., 1984), mutant PfCRT can mediate the removal of CQ from the DV, which 
forms the basis of CQ resistance (Roepe, 2009). However, two opposing schools of thought 
have tried to explain the pfcrt linked mechanism of CQ removal from the DV. One view 
postulates that PfCRT is a channel. Supporters of the channel model have claimed that K76T 
leads to loss of a positive charge, which in case of CQS PfCRT repels the diprotonated CQ 
found in the DV, but its loss in CQR PfCRT allows positively charged CQ to flow out of the 
vacuole along the proton gradient across the DV membrane (Warhurst et al., 2002, Bray et al., 
2006, Zhang et al., 2004). In this scheme, verapamil restores the loss of positive charge, 
thereby blocking CQ outflow from the DV and sensitizing CQR parasites to CQ. Opponents 
of the channel hypothesis have presented evidence in favour of a PfCRT linked, energy 
dependent, verapamil sensitive and substrate specific efflux mechanism for CQ (Sanchez et 
al., 2005, Sanchez et al., 2004, Sanchez et al., 2007b). These authors argue that PfCRT is a 
carrier protein, and mutations change the affinity of the carrier for its substrate. Trans-
stimulation experiments aimed at differentiating between channels and carriers have 
demonstrated that PfCRT linked CQ efflux can be trans-stimulated with CQ as well as 
quinoline substrates such as QN, QD and AQ (Sanchez et al., 2007a, Sanchez et al., 2003). 
Other reports also support the carrier model. These include mathematical analyses of the CQ 
transport data pertaining to the two opposing models (Chinappi et al., 2010) as well as PfCRT 
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expressing oocytes that show saturation kinetics for CQ uptake (Martin et al., 2009b, 
Summers & Martin, 2010). Another set of studies has revealed the presence of a CQ linked 
leak of protons from the DV which is more enhanced in CQR parasites than in CQS parasites, 
and which can be reversed using CQR sensitizers (Lehane & Kirk, 2010, Lehane & Kirk, 
2008). Taken together, these data sets support a model where PfCRT acts as a carrier for CQ, 
and transports the drug from the DV in association with protons (Sanchez et al., 2007b).  
 
PfCRT resides in the DV membrane, has a molecular weight of 45 KDa and is composed of 
424 amino acid residues (Sanchez et al., 2010). Kuhn et al. have shown that the trafficking of 
PfCRT to the DV membrane involves the phosphorylation of a threonine residue at position 
416 (Kuhn et al., 2010). Bioinformatic analyses predict PfCRT to possess 10 transmembrane 
domains, with the N and the C-terminal facing the parasite cytoplasm, and it to be a member 
of the drug metabolite transporter superfamily (Martin & Kirk, 2004). Transmembrane 
domains of PfCRT show pseudosymmetry; such an internal symmetry is a characteristic of 
many carrier proteins (Sanchez et al., 2010). While there is increasing agreement for PfCRT 
to be a CQ carrier, knowledge about its natural substrate remains a holy grail. Martin et al. 
successfully inhibited CQ transport in oocytes expressing the PfCRT Dd2 allele with a range 
of oligopeptides, whereas no inhibition was observed with amino acids, di- or tri-peptides. 
They also showed uptake for one tetrapeptide that could inhibit CQ uptake (Martin et al., 
2009a). This raises the possibility that PfCRT may transport peptides from the DV to the 
parasite cytoplasm, and this fits with the DV being an organelle for hemoglobin degradation. 
However, this claim remains on shaky ground as peptide uptake in this report was seen only 
for the CQR allele (Dd2) and not for the CQS allele (CQS). Another group has expressed clt 
(CRT like transport) - an Arabidopsis thaliana homologue of PfCRT in X. laevis oocytes 
(Maughan et al., 2010). These authors show that clt mediates glutathione uptake upon 
expression in oocytes. No evidence showing glutathione transport by PfCRT is yet published, 
although glutathione metabolism and CQ resistance have been linked in the past (Meierjohann 
et al., 2002).  
 
But the role of PfCRT is not limited to CQ transport alone. PfCRT has been implicated in 
altered suscepitibilites to amodiaquine, quinine, quinidine, amantadine and halofantrine 
(Fidock et al., 2000, Ferdig et al., 2004, Sidhu et al., 2002, Cooper et al., 2002, Cooper et al., 
2007, Sa et al., 2009). Martin et al. have confirmed that PfCRT can interact with antimalarial 
drugs other than CQ. They were able to inhibit PfCRT Dd2 associated CQ transport in 
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X. laevis oocytes with amodiaquine, quinine, quinidine, quinacrine, verapamil at low 
concentrations and with primaquine & mefloquine at higher concentrations (Martin et al., 
2009a). It is thought that chemical structures require a hydrogen bond acceptor and two 
hydrophobic aromatic rings to be able to interact with PfCRT (Bhattacharjee et al., 2002, van 
Schalkwyk & Egan, 2006). More recently, N-benzyl-N-methyl-1-phenylmethanamine 
derivatives have been shown to inhibit CQ transport in PfCRT expressing oocytes (Zishiri et 
al., 2011). Understanding the interaction between PfCRT and compounds other than CQ is all 
the more important because modified CQ analogues and many other compounds are being 
pursued as potential antimalarial drugs (Schlitzer, 2007). Moreover, drugs such as 
amodiaquine and quinine, which share the mechanism of action of CQ, are still in use. Thus, 
studying drug transport properties of PfCRT remains a relevant issue. One way of measuring 
an interaction between PfCRT and compounds such as CQ, quinine and quinidine would be to 
express the protein heterologously. This would allow a determination of substrate transport 
kinetics without being influenced by non-PfCRT parasite factors; these can complicate such 
determinations if performed in situ.  
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1.4  Use of Xenopus laevis oocytes to study membrane 
proteins 
 
 
Fig 1.6: An Adult female Xenopus laevis (left) and its oocytes after surgical removal (right) 
 
Heterologous expression of PfCRT has been achieved in the past, in the yeast Pichia pastoris 
(Zhang et al., 2002, Zhang et al., 2004), in Dictyostelium discoideum (Naude et al., 2005, Sa 
et al., 2006)  and also in X. laevis oocytes (Nessler et al., 2004). PfCRT containing vesicles 
and proteoliposomes have also been reconstituted from yeast (Tan et al., 2006, Paguio et al., 
2009). In a more recent piece of work, Martin et al. have expressed a modified form of 
PfCRT in X. laevis oocytes and shown time dependent, saturable, verapamil sensitive and 
quinoline inhibitable uptake of CQ (Martin et al., 2009a).  
 
Oocytes of the South African clawed frog Xenopus laevis have been used to study proteins 
since John Gurdon introduced their application to biological sciences in late 1950s (Brown, 
2004, Kashiwagi et al., 2010). The oocyte is a relatively large cell; stage V-VI oocytes have 
an average diameter of 1 to 1.3 mm (Kashiwagi et al., 2010, Weber, 1999). This facilitates 
injection of foreign RNA into the oocyte cytoplasm. Gurdon and his colleagues successfully 
synthesized rabbit globin by injecting its mRNA in cytoplasm of X. laevis oocytes (Gurdon et 
al., 1971). This technique got further enhanced when Douglas Melton established a method to 
synthesize synthetic RNA and express it in oocytes (Krieg & Melton, 1984). Since then, 
X. laevis oocytes have found their way as an experimental system in a wide variety of 
biological disciplines (Brown, 2004, Miller & Zhou, 2000). X. laevis oocytes have been 
particularly useful in studying membrane transport processes, by expressing membrane 
carriers and channels in these cells. This is largely because an extended range of techniques 
such as two-electrode voltage clamp, cut-open technique, giant patch clamp, ion selective 
electrodes to measure intracellular ion concentrations, tracer efflux and influx experiments, 
concentration jump technique, confocal microscopy, binding assays and volume 
Introduction 
 27
measurements can be applied to oocytes (Weber, 1999). It is therefore no surprise that 
X. laevis oocytes have also been employed in investigating membrane transport proteins of 
the malaria parasite. These include the digestive vacuolar Plasmodium falciparum multidrug 
resistance protein 1 (Sanchez et al., 2008a), PfATP6 which is the homologue of the sarco-
endoplasmic reticulum Ca2+ ATPase (Eckstein-Ludwig et al., 2003) , the mitochondrial Ca2+ 
/H+exchanger PfCHA1 (Rotmann et al., 2010), a hexose transporter PfHT1 (Krishna & 
Woodrow, 1999) and a sodium dependent transporter of inorganic phosphate PfPiT(Saliba et 
al., 2006). Expression of PfCRT in X. laevis oocytes was thus an attractive choice for a 
method to answer the questions asked as part of this study.  
 
1.5  Aim of the study  
 
Understanding the role of PfCRT in mediating resistance to quinolines and arylaminoalcohols 
has been an area of considerable interest in malaria research. A number of studies mentioned 
in the previous sections have done so and advanced our knowledge of drug resistant malaria. 
However, such attempts have traditionally concentrated on three aspects of quinoline 
transport in the malaria parasite – one is the relationship between mutant pfcrt and resistance 
to a particular drug measured in terms of IC50 values (Fidock et al., 2000, Sidhu et al., 2002), 
second is the extent to which loci other than pfcrt as well as the genetic background of the 
parasite modulate resistance to quinolines (Ferdig et al., 2004, Mu et al., 2003), and thirdly 
the actual mechanism and kinetics of PfCRT linked quinoline transport in the parasites 
(Sanchez et al., 2004, Sanchez et al., 2007a, Sanchez et al., 2003). The influence of point 
mutations has been studied mainly for the K76T mutation (Lakshmanan et al., 2005, Cooper 
et al., 2002). Cooper and colleagues have shown that mutations in transmembrane domains 
1,4 and 9 alter susceptibility to quinolines (Cooper et al., 2007). However, this study 
concentrated on amino acid substitutions selected under in vitro drug pressure, and not the 
point mutations found in pfcrt isolates from the world over. The objective of this project was 
to investigate role of mutant PfCRT polymorphisms in transport of quinolines. Another aim 
was to try and establish if PfCRT can transport substrates other than chloroquine. It was 
proposed, as part of this study, to express a number of pfcrt alleles in X. laevis oocytes and 
subsequently carry out uptake measurements with radiolabelled substrates, so as to be able to 
answer the questions being raised.  
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2  Materials and methods 
2.1  Materials 
 
2.1.1  Equipments 
 
Analytical scales Sartorius, Göttingen 
Autoclave Tuttnauer Systec 2540, Wettenberg 
Camera, DC 120 Zoom Digital Intas, Germany 
Centrifuges    
 Biofuge fresco Heraeus Instruments, Hanau 
 Biofuge pico Heraeus Instruments, Hanau 
 J2-MC Beckman, Krefeld 
 L-60 Ultracentrifuge Beckman, Krefeld 
 Megafuge 1.0 R Heraeus Instruments, Hanau 
 RC5BPlus Sorvall, Langenselbold 
Computer Software 
 Adobe Photoshop ®5.0  Adobe Systems Inc, USA 
 EndNote 8.0. ISI Research Soft, CA, USA 
 Internet Explorer Microsoft Corporation, USA 
 MS Powerpoint Microsoft Corporation, USA 
 MS Word 2000 Microsoft Corporation, USA 
 SigmaPlot 11.0 Systat Software Inc. 
DNA-electrophoresis apparatus Biorad, München 
Transjector 5246 Eppendorf, Germany 
Freezer -80°C, UF85-300S^  Heraeus GmbH, Hanau 
Freezers -20°C  Liebherr, Biberach 
Fridges   Liebherr, Biberach 
Gas burner gasprofi 1 micro  WLD-TEC 
Glass capillaries GB100F10  Scientific products GmBH, Germany 
Ice machine AF 30  Scotasman, Milano, Italy 
Incubator (ooyctes)  Memmert 
Liquid nitrogen tank   Air Liquide, Ludwigshafen 
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TR-CARB 2100 TR  Packard 
Liquid scintillation counter 
Magnetic stirrer   Heidolph, Schwabach 
Microscopes 
Light optical microscope Zeiss, Jena 
Axiolab Leica DMII Leica 
Light microscope  
Microwave oven  AEG, Nürnberg 
PCR machine 
T gradient Thermocycler Biometra, Göttingen 
pH-Meter pH 537  WTW, Weilheim 
Pipetman Gilson P10, P20, P1000  Abimed, Langenfeld 
Pipetus-akku  Hirschman labortechnik, Eberstadt 
pipetus® standard Hirschman labortechnik, Eberstadt 
Power supply : Power Pac 300  Biorad, München 
Rotor JA20.1  Beckman instruments, USA 
Spectrometer UVIKON 923  Kontron Instruments 
Sterile work bench Herasafe  Heraeus Instruments, Hanau 
Stopwatch  Roth, Karlsruhe 
Tweezers  Dumont, Switzerland 
UV-table UV –Transilluminator  Gibco BRL, Karlsruhe 
Vortex Genie 2  Roth, Karlsruhe 
Watherbath Julabo 7A  Julabo Labortechnik, Seelbach  
 
2.1.2 Disposables  
Aluminium foil  Roth, Karlsruhe 
Centrifuge tubes, Polypropylene   Greiner Bio-one, Frickenhausen 
18/95   
Clingfilm Saran  Dow Chemical Company, Schwalbach 
Cuvettes  Saarstedt, Nümbrecht, Germany 
Eppendorf tubes  Saarstedt, Nümbrecht, Germany 
Falcon tubes (15 ml, 50 ml)  Corning incorporation, Bodenheim 
Gloves  Harmann, Heidenheim 
Immersion oil  Zeiss, Jena 
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Kimwipes lite 200  Kimberly Clark 
Parafilm  Americal International CanTM, USA 
PCR softtubes 0.25 ml  Biozym Scientific GmbH 
Petri dishes (10 ml diameter) Greiner Bio-one, Frickenhausen 
Petri-dishes (25 ml diameter)  Greiner Bio-one, Frickenhausen 
Pipette Tipps  Corning Inc, Bodenheim 
Plastic pipettes   Corning Inc. Bodenheim 
(1 ml; 2 ml; 5 ml; 10 ml; 25 ml) 
Radioactive Vials 
            Mini PolyQ vials 6 ml  Beckman Instruments Inc., USA 
Sterile filters (0,2 µm)  Millipore GmbH, Ashburn 
Stiches 
Sterile filtration devices  Corning incorporation, Bodenheim 
Thermowell PCR tubes  Corning incorporation, Bodenheim 
X-ray film  Kodak  
 
2.1.3 Chemicals  
2.1.3.1 Non-radioactive chemicals 
The non-radioactive chemicals for the purpose of this study were purchased from the firms 
Roth, Merck, Sigma, Serva and Applichem. These were either ordered directly or through the 
chemicals facility of the University of Heidelberg medical school.  
Non-radioactive quinoline drugs used in uptake experiments were purchased from following 
sources 
Chloroquine Chloroquine Disphosphate, Sigma, Germany.  
Quinine Quinine Hydrochloride, Sigma, Germany.  
Quinidine Quinidine Sulphate, Sigma, Germany.  
Verapamil Verapamil Hydrochloride, Sigma, Germany.  
2.1.3.2 Radioactive chemicals  
[3H]-chloroquine 25 Ci mmol-1 Amersham Radiolabelled chemicals 
[3H]-quinine 20 Ci mmol-1  Amersham Radiolabelled chemicals 
[3H]-quinidine 20 Ci mmol-1 Amersham Radiolabelled chemicals 
[3H]-amodiaquine 09 Ci mmol-1 Amersham Radiolabelled chemicals 
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2.1.4 Kits  
Gel extraction kit  QIAGEN® 
PCR purification kit  QIAGEN® 
High pure plasmid miniprep Kit Roche, Mannheim 
Plasmid maxiprep kit  QIAGEN®  
in vitro RNA transcription kit  Ambion , U.S.A.  
(mMessage mMachine SP6) 
Enhanced Chemiluminescence kit Pierce® , U.S.A.   
 
2.1.5  Biological materials  
2.1.5.1 Size Markers and loading buffer 
6 x DNA loading buffer    Fermentas, Germany.  
GeneRuler 1 Kb DNA ladder plus  Fermentas, Germany.  
2x Protein loading buffer     
PageRuler Plus  Prestained protein ladder  Fermentas, Germany.  
(SM1811)  
2.1.5.2 Enzymes 
Collagenase Type IA  Sigma, Mannheim, Germany.  
EuroTaq polymerase  BioCat GmbH, Heidelberg, Germany. 
Phusion Polymerase  Fermentas, Germany.  
Restriction Enzymes   New England Biolabs 
(XhoI, AvrII, BamHI, PstI, BglII)  
Shrimp Alkaline Phosphatase  Promega 
T4 DNA Ligase  Invitrogen 
 
2.1.5.3 Plasmids 
pfcrt alleles used in the study were cloned into the pSP64T vector (Krieg & Melton, 1984). 
For facilitating cloning, XhoI and AvrII sites were first introduced in the pSP64T vector and 
this vector was used for all subsequent cloning steps.  
 
P. falciparum coding sequences, which harbour AT rich sequences and therefore display a 
codon bias, are optimized to a yeast codon usage for facilitating heterologous expression 
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(Zhang et al., 2002, Nessler et al., 2004, Birkholtz et al., 2008). To this end, pfcrt haplotypes 
from the strain HB3, Dd2, 7G8 and Ph1 were synthesized by GENEART AG (Regensburg) 
and then subcloned into the pSP64T vector using XhoI and AvrII sites. All the other alleles, 
which used for the purpose of this study, were synthesized through mutagenesis by using the 
appropriate template from the above mentioned pfcrt coding sequences.  
2.1.5.4 Oligonucleotides  
All oligonucleotides were purchases from Thermo Electron GmbH (Ulm).  
Sequencing primers 
SP6-66 FP 5’GCTTGTACATATTGTCGTTAGAACG 3’ 
PfCRT+731 FP 5’GATTGAACGCTATGGTTTC 3’ 
pSP64T RP 5’GTAAGTTGGGTATTATGTAGC 3’ 
Primers for megaprimer synthesis 
5’Globin FP 5’GCAGAAGCTCAGAATAAACGCTCAAC 3’ 
3’ Globin RP 5’ GTAGCTTAGAGATCCCATTCG 3’ 
PfCRT 7G8 S72C FP 5’ CTTGTCTGTTTGCGTCATGAAC 3’ 
PfCRT 7G8 S72C RP 5’ CGTGTTAATGACGCAAACGGAC 3’ 
PfCRT Ph1 C72S FP 5’ CTTGTCTGTTAGCGTCATGAAC 3’ 
PfCRT Ph1 C72S RP 5’ CGTGTTAATGACGCTAACGGAC 3’ 
PfCRT HB3 K76T FP 5’ CACAAACGCAGTACTTGTGCTAGAAG 3’ 
PfCRT HB3 K76T RP 5’ GAAGATCGTTTGAATGACGCAAACAC 3’ 
PfCRT Ecu1110 T76K FP     5’ GTCTGTTTGCGTCATGAACAAGATCTTCG 3’ 
PfCRT Ecu1110 T76K RP     5’ GAAGATCTTGTTCATGACACGAACAC 3’ 
PfCRT S220A FP 5’ GATTTCCGCATTGATTCCAGTTTGTTTCTCC 3’ 
PfCRT S220A RP 5’ GGAGAAACAAACTGGAATCAATGCGGAAATC 3’ 
PfCRT S326D FP 5’ CTCCTTCTTCGACATTTGCGATAACTTG 3’ 
PfCRT S326D RP 5’ GTGATCAAGTTATCGCATAAGTCAAGAAGG 3’ 
PfCRT D326N FP 5’ CTCCTTCTTCAACATCTGCGATAAC 3’ 
PfCRT D326N RP 5’ GTTATCGCAGATGTTGAAGAAGAAG 3’ 
PfCRT L356I FP 5’ GTCCAGCTATTGCTATTGCCTAC 3’ 
PfCRT L356I RP 5’ GCAATAGCAATAGCTGGACCTTG 3’ 
PfCRT T356I FP 5’ GTCCAGCTATTGCTATTGCCTAC 3’ 
PfCRT T356T RP 5’ GCAATAGCAATAGCTGGACCTTG 3’ 
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2.1.5.5 Bacteria  
 
E. coli strain XL1 Blue was used for cloning and propagation of the plasmid.  
2.1.5.6 Antibodies  
Antigen Isotype Raised in Company 
Anti-PfCRT Polyclonal Guinea pig  
Anti-alpha Tubulin Monoclonal Mouse Sigma, Germany 
Anti-mouse conjugated with  
peroxidase Monoclonal Donkey 
Jackson 
Immunoresearch 
Anti-guineapig conjugated with 
peroxidase Monoclonal Donkey 
Jackson 
Immunoresearch 
 
2.1.5.7  Xenopus laevis frogs  
Adult female Xenopus laevis frogs were purchased from NASCO, U.S.A. and maintained in 
the animal facility of the Interfakultär Biomedizinisches Forschungszentrum (IBF) of the 
University of Heidelberg medical school. Frogs were maintained in water tanks at a 
temperature of 18°C and fed thrice a week with food pellets. Frogs were 2 years of age at the 
time of purchase.  
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2.1.6  Buffers, media and solutions 
Ampicillin stock, 100 x    50 mg/ml in ddH2O 
 
Anesthetic solution   0.1% (w/v) Ethyl 2-aminobenzoate 
methane sulfonate in tap water 
 
APS    10% (w/v) APS in ddH2O 
 
Blocking solution    5% (w/v) skimmed milk in PBS 
 
Coomassie Destaining solution    5% methanol 
    10% acetic acid 
 
Coomassie Staining solution    5% methanol 
    10% acetic acid 
    0.0.5% Coomassie Brilliant Blue R-250 
 
DNA loading buffer, 6 x    9 mg Bromophenol blue 
    9 mg Xylene Cyanol FF 
    Dissolve in 8.8 ml of 60% Glycerol and
    add 1.2 ml of 0.5 M EDTA 
 
LB broth    10 g Tryptone 
    5 g yeast extract 
    5 g NaCl 
    Dissolve in 1 l ddH2O and autoclave 
 
LB agar    10 g Tryptone 
    5 g yeast extract 
    5 g NaCl 
    15 g Agar 
    Dissolve in 1 l ddH2O and autoclave 
 
ND96, pH 7.5    96 mM NaCl 
    2 mM KCl 
    1 mM MgCl2 
    1.8 mM CaCl2  
    10 mM HEPES 
    Set pH to 7.5 with NaOH and autoclave 
 
ND96, pH 6.0    96 mM NaCl 
    2 mM KCl 
    1 mM MgCl2 
    1.8 mM CaCl2  
    10 mM Tris 
    10 mM HEPES, pH 7.5 
    Set pH to 6.0 with HCl 
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OR2    96 mM NaCl 
    2 mM KCl 
    1 mM MgCl2 
    10 mM HEPES 
    Set pH to 7.5 with NaOH and autoclave 
 
RIPA buffer      100 mM Tris.HCl pH 7.4 
150 mm NaCl 
1 mM EDTA 
1% Triton X-100 
1% Sodium Deoxycholate 
0.1% SDS 
 
RNA gel running buffer, 20 x     20 mM MOPS 
      2 mM Sodium Acetate 
    0.25 mM EDTA 
 
SDS loading buffer, 2 x     8 M Urea 
       5 % (w/v) SDS 
       40 mM Tris.HCl pH 6.8 
       0.1 mm EDTA 
       0.4 mg/ml Bromophenol blue 
 
SDS-PAGE running buffer    25 mM Tris 
    192 mM Glycine 
    0.1% SDS 
 
Semi-dry transfer buffer    48 mM Tris 
39 mM Glycine 
0.38% (w/v) SDS 
 
SOB    20 g Tryptone 
    5 g Yeast extract 
    0.5 g NaCl 
    0.186 g KCl 
    Dissolve in 1 l ddH2O and autoclave 
 
SOC    SOB with 20 mM Glucose 
 
 
Stripping buffer     50 mM Tris pH 6.8 
2 % SDS 
100 mM 2-Mercaptoethanol 
 
Super broth    35 g Tryptone 
    30 g yeast extract 
    5 g NaCl 
    Add 1 l ddH2O 
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TAE    40 mM Tris-acetate 
    1 mM EDTA (pH 8.0) 
 
TB Buffer      10 mM PIPES 
15 mM CaCl2 
55 mM MnCl2.4H2O 
250 mM KCl 
Dissolve all components except MnCl2. 
Set pH to 6.7 with KOH 
Then add MnCl2, mix and filter sterilize 
by passing through 0.2 mm  filter.  
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2.2  Methods  
 
2.2.1 Microbiological methods  
2.2.1.1 Preparation of chemocompetent E. coli cells 
 
Bacterial cells that are able to take up foreign DNA molecules such as plasmids are termed 
“Competent cells”. Chemically competent cells were prepared with a method involving 
DMSO (Inoue et al., 1990). E. coli XL1 blue cells were streaked on a L.B. Agar plate and 
grown overnight at 37°C. Thereafter a single colony was used to inoculate 5 ml SOB medium 
and the culture allowed to grow overnight at 37°C, shaking at 230 rpm. The following day the 
5 ml overnight culture was used as a started culture to inoculate 250 ml of SOB medium, 
grown in a 2 liter flask at 37°C and shaking at a rotational speed of 230 rpm, till a O.D.600 
value of 0.6 units was attained. The culture was then chilled on ice for 10 minutes, and 
subsequently centrifuged at 6000 rpm, 4 °C for 15 minutes. Supernatant was discarded, the 
pellet re-suspended in 80 ml of ice-cold CC buffer and chilled on ice for 10 minutes, after 
which it was centrifuged at 6000 rpm, 4 °C for 15 minutes. The supernatant was discarded 
and pellet re-suspended in 20 ml of ice-cold CC buffer, after which 1.4 ml of DMSO was 
added to the re-suspended cells while stirring gently. Cells were chilled on ice for 10 minutes 
and then aliquoted in 50 µl aliquots in microcentrifuge tubes placed in a bath of dry ice and 
ethanol. Immediately after aliquoting cells, the tubes were closed and stored at -80 °C for 
further use.  
2.2.1.2 Transformation of competent E. coli  
 
Transformation of competent bacteria refers to the process by which DNA molecules are 
inserted in the cells, and was carried out using a heat-shock (Inoue et al., 1990). Briefly, 50 µl 
of chemocompetent E. coli XL1 Blue cells (stored at -80 °C) were thawed on ice, to which 
10 µl of a ligation sample or a desired amount of a supercoiled DNA sample was added. After 
mixing by gently tapping the base of the tube the mixture was incubated on ice for 30 
minutes. The samples were thereafter placed in a water bath at 42 °C for 45 seconds, and then 
immediately placed on ice for 2 minutes, after which 1000 µl of SOC medium, pre-warmed at 
37 °C ,was added. This mixture was incubated at 37 °C for 1 hour, while shaking at 230 rpm. 
100 µl of this transformed medium was plated on L.B.Agar plates containing 100 µg/ml 
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Ampicillin, and the plates were incubated overnight at 37 °C. Plates were checked the 
following days for growth of bacterial colonies, where each colony represented growth from a 
single clone.  
2.2.1.3 Glycerol-stocks of Bacteria 
 
In order to maintain bacterial cells for long term storage, they are routinely stored at -80 °C in 
form of glycerol-stocks. These were prepared by mixing 800 µl of bacterial culture with 200 
µl of 100% sterile glycerol. For further use, such a stock was not thawed but cells were 
simply scratched off the surface with a pipette tip and subsequently used to inoculate a starter 
culture.  
 
2.2.2 Molecular biology methods  
2.2.3.1 Photometric determination of DNA/RNA concentration 
 
Nucleic acids can absorb UV light with an absorption maximum at 260 nm. The amount of 
light absorbed is related to the concentration of the absorbing molecule as per Beer Lambert’s 
law, using which an extinction co-efficient of 0.020 (µg/ml)-1 cm-1 for double-stranded DNA 
and of 0.020 (µg/ml)-1 cm-1 for single-stranded RNA have been calculated. Thus, an O.D.260 of 
1 Unit corresponds to 50 µg/ml of DNA and 40 µg/ml of RNA.  
 
To measure concentration in DNA samples, a UVIKON 923 spectrophotometer (Kontrol 
Instruments) was used. DNA or RNA samples were diluted 1:100 and absorbance at 260 nm 
was measured for the same. The concentration of DNA or RNA sample was calculated from 
the O.D.at 260 nm.  
2.2.3.2 Agarose gel Electrophoresis of nucleic acids 
 
Agarose, a linear polymer of agarobiose, exhibits the property of melting at 85°C and 
solidifying at 32 - 40°C. It can therefore be mixed with a buffer, boiled, poured into a mould 
and then allowed to solidify. Migration of nucleic acids in an electric field is dependent on 
size and conformation. The sizes of pores within such an agarose gel can manipulated by 
increasing or decreasing the amount of agarose added. Low concentration of agarose is used 
to separate large nucleic acid fragments, whereas high concentration is used when isolating 
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small fragments. DNA fragments ranging between 0.1 and 25 kb in size can be separated in 
agarose gels.   
2.2.3.2.1 Gel Electrophoresis of DNA 
 
1% agarose gels were prepared by adding appropriate amount of solid agarose powder to TAE 
buffer, and the mixture was boiled in microwave till the agarose dissolved. After the 
temperature of this mixture was below 60°C, Ethidium bromide was added to a final 
concentration of 1 µg/ml and the mixture poured in a gel cast. Ethidium bromide gets 
degraded above 60°C, hence the need to cool down the gel. It intercalates with nucleic acids 
and fluoresces under UV illumination. 6 x DNA loading buffer was added to DNA samples to 
a final concentration of 1 x and samples were then loaded on the gel. 1 Kb Plus DNA 
Ladder™ was run alongside the samples as a size marker. Electrophoresis was carried out for 
60 minutes at a constant voltage of 90 V for a small gel and 120 V for a big gel. Samples were 
photographed under UV illumination using a DC120 Zoom Digital camera (Kodak).  
2.2.3.2.2 Gel electrophoresis of RNA 
 
Agarose gel electrophoresis of RNA was carried out slightly differently than that for DNA, in 
that the agarose used was of special grade so as to minimize endosmosis. RNA can form 
secondary structures due to its single stranded nature. Formaldehyde was therefore used in the 
gels to maintain it in a denatured condition, so that the migration pattern would mainly be due 
to differences in its length. To this end, gels were prepared as under: 
 
Agarose     0.28 g 
H2O     30 ml 
20 x RNA gel  running buffer    2 ml 
Boiled in autoclave, cooled down to 50-60 °C, then 0.5 µl of EtBr added and poured in gel 
mould. After gel solidified, 8 ml of 37% formaldehyde was added on its surface, kept for 1 
min and then removed. Electrophoresis was carried out using RNA gel running buffer for 60 
min at 60 V, after which a photograph was taken under UV illumination.  
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2.2.3.4 Restriction digestion of DNA 
 
DNA can be enzymatically cleaved by restriction endonucleases. These enzymes recognize 
short, often palindromic sequences and catalyze a break in the sugar-phosphate backbone of 
DNA by hydrolysis. The resulting fragments have either “blunt” or “sticky” ends depending 
on the type of enzyme used. Sticky ends refer to the single-stranded overhang of a few 
nucleotides produced as a result of the cleavage, whereas in case of blunt ends no such 
overhang is found. Sticky ends are particularly useful since these anneal specifically to a 
complimentary overhang, and a ligation between two different fragments of DNA can thus be 
catalyzed in a desired orientation.  
 
Restriction digestion was carried out to prepare vector and insert fragments for cloning, for 
checking plasmid DNA obtained from bacterial colonies and for linearizing plasmid DNA to 
be used for in vitro RNA transcription. Digests were set up as under:  
 
Preparation of vector DNA      Preparation of insert DNA 
H2O   as needed     H2O   12 µl 
Plasmid DNA    3 µg     PCR insert  30 µl 
10 x Buffer    5 µl     10 x Buffer    5 µl 
10 x BSA    5 µl     10 x BSA    5 µl 
XhoI     1 µl     XhoI     1 µl 
AvrII     2 µl     AvrII     2 µl 
Total Volume  50 µl     Total Volume  50 µl 
Incubated overnight at 37°C      Incubated overnight at 37°C 
 
 
Analysing plasmid minipreps     Linearizing plasmid 
H2O   11  µl     H2O   as needed 
Plasmid miniprep   4  µl     Plasmid DNA    20 µg 
10 x Buffer    2  µl     10 x Buffer    10 µl 
10 x BSA    2  µl     10 x BSA    10 µl 
XhoI   0.5 µl     BamHI      4 µl 
AvrII   0.5 µl      
Total Volume  20  µl     Total Volume  100 µl 
Incubated 60 min at 37°C     Incubated overnight at 37°C 
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2.2.3.5 Extraction and purification of DNA 
2.2.3.5.1 Agarose gel extraction 
Vector and insert DNA fragments as well as PCR samples were fractionated by subjecting the 
samples to agarose gel electrophoresis. This enabled isolation of specific fragments of 
required length, and the DNA fragment therein was purified using QIAGEN Gel extraction 
kit. The kit involved solubilizing the agarose gel slice by melting at 50°C, after which the 
sample was allowed to flow through a QIAquick™ membrane. This is a silica membrane 
which adsorbs DNA in presence of high concentrations of salt whereas the contaminants flow 
through. After washing steps, DNA was eluted in low salt conditions with Tris buffer or water 
provided in the kit.  
2.2.3.5.2 PCR Column purification 
This method was used to purify restriction digested PCR products, using QIAGEN 
purification kit. The principle behind the method involved adsorption of DNA onto a silica 
membrane in presence of high salt concentration and elution with a low salt buffer or water.  
2.2.3.5.3 Phenol-Chloroform precipitation  
Concentration, recovery and desalting of nucleic acids is routinely done using alcohol. 
Proteins in a reaction mixture can be denatured using Phenol-Chloroform and the nucleic acid 
can eventually be precipitated using high concentration of salt in presence of an alcohol.  
 
Plasmid DNA was precipitated after linearization using this protocol. After digestion, 100 µl 
of the digest was mixed with 100 µl of Phenol:Chloroform:Isoamylalcohol::23:24:1. The 
sample was vortexed and centrifuged at 8000 rpm for 5 minutes in a microcentrifuge. The 
aqeous layer lying on the top was extracted with a pipette and transferred to a fresh tube. To it 
a 1/10 x volume of 3 M Sodium Acetate, pH 5.2 and 2 x volume of Isopropanol were added. 
The sample was vortexed, maintained at -20°C for 60 min and then centrifuged for 30 min at 
13000 rpm in a microcentrifuge. DNA formed a pellet at the bottom of the tube, while the 
supernatant was removed. The pellet was washed with 1 ml of ice-cold 70% Ethanol (v/v) and 
then with 1 ml of 100% Ethanol, after which pellet was air dried and dissolved in 20 µl of 
water.  
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2.2.3.6 Dephosphorylation of DNA ends  
 
When a ligation reaction between two DNA fragments is attempted, three possibilities arise: 
(1) Ligation between two ends of the vector fragment (2) Ligation between two ends of the 
insert fragment and (3) Ligation between one end of insert with another end of vector 
fragment. Scenario no.3 represents the desirable outcome, whereas scenario no.2 would not 
lead to viable colonies with bacterial cells after transformation as long as it lacks a selection 
marker. On the contrary re-ligation of vector fragment, that contains a selection marker, can 
lead to colonies. Moreover, the likelihood that two ends of the same DNA fragment collide 
with each other is much higher than that for meeting of two ends from two different 
fragments. To avoid this, use is made of the fact that ligation of two DNA ends requires a 
5’phosphate and a 3’hydroxyl group. Re-ligation of vector ends can thus be avoided by 
removing its phosphate groups. This is done by treatment with an alkaline phosphatase which 
can be heat inactivated so that it does not interfere in subsequent ligations. The reaction set-up 
used was as under: 
Vector digest     50 µl 
10 x SAP buffer     6 µl 
SAP        1 µl 
Incubated at 37°C for 30 minutes and then heat inactivated at 65°C for 15 minutes.  
2.2.3.7 Ligation of DNA fragments  
 
Replication and repair of DNA in cells involves the action of DNA ligases. One such enzyme 
is the T4 DNA ligase isolated from the T4 bacteriophage. It catalyzes an ATP-dependent 
formation of a phosphodiester bond between 5’-phosphate and 3’-hydroxyl groups present at 
DNA termini. This enzyme can join both blunt and cohesive ends (Rossi et al., 1997). It 
therefore allows ligation of different DNA fragments and is extensively used in cloning. The 
plasmid DNA where another DNA fragment is inserted is called “vector”, whereas the 
inserted fragment is termed “insert”. It has been observed that ligation efficiency is optimal 
when the insert is in molar excess to the vector. Ligation reactions were set up as below: 
 
Dephosphorylated DNA vector    0.5 µl 
Insert fragment      6.5 µl 
5 x Ligase buffer      2.0 µl 
T4 DNA Ligase (1U/µl)     1.0 µl 
Total Volume     10.0 µl 
Incubated at RT for 2 hours, then transformed into competent E.coli.  
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Similarly, a vector control was set up where H2O was added instead of insert. 
2.2.3.8 Polymerase chain reaction  
 
DNA sequences can be amplified in vitro using a Polymerase chain reaction (PCR) which 
involves a temperature dependent DNA polymerase, a template DNA sequence and 
oligonucleotide primers that bind to the the template (Saiki et al., 1985). PCR was used to 
amplify pfcrt sequences for cloning as well, for screening bacterial colonies as well as to 
introduce mutations at specific positions within the coding sequence.  
2.2.3.8.1 Site-directed mutagenesis via megaprimer synthesis  
 
In order to mutate specific amino acid residues in the PfCRT sequence, megaprimers were 
first synthesized by employing oligonucleotides with the desired mutation. This PCR was set 
up as follows:  
Reaction set-up for megaprimer PCR  Cycling conditions 
H2O    10.5  µl  Initial denaturation :  98°C 5 min 
5 x Phusion HF Buffer   5.0  µl  Denaturation  :  98°C 30 sec 
50 mM MgCl2    1.5  µl  Annealing  : 62°C 15 sec 
10 mM dNTP mix    2.0  µl  Extension  : 72°C 20 sec 
Template (1 ng/µl)  10.0  µl  Final extension : 72°C 5 min 
2.5 µM FP   10.0  µl 
2.5 µM RP   10.0  µl  No. of cycles  : 30  
Phusion Polymerase    1.0  µl 
Total Volume   50.0  µl 
 
PCR reactions were then subjected to agrose gel electrophoresis and bands of appropriate 
length were excised and DNA purified. Using these DNA fragments as megaprimers, another 
set of PCR was performed as follows: 
 
Reaction set-up for second PCR   Cycling conditions 
H2O    10.5  µl  Initial denaturation :  98°C 5 min 
5 x Phusion HF Buffer   5.0  µl  Denaturation  :  98°C 30 sec 
50 mM MgCl2    1.5  µl  Annealing  : 62°C 15 sec 
10 mM dNTP mix    2.0  µl  Extension  : 72°C 30 sec 
Megaprimer-1     2.0  µl  Final extension : 72°C 5 min 
Megaprimer-1     2.0  µl 
2.5 µM 5’ Globin FP  10.0  µl 
2.5 µM 3’ Globin RP  10.0  µl  No. of cycles  : 30  
Phusion Polymerase    1.0  µl 
Total Volume   50.0  µl 
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Full length pfcrt coding sequence was yielded in this PCR. Ater agarose gel purification, it 
was digested with XhoI and AvrII restriction enzymes. The digested fragment was used for 
cloning after DNA purification achieved with QIAGEN PCR purification kit.  
2.2.3.8.2 Colony PCR 
 
Colonies obtained after transformation were screened with a PCR to fish out positive cloness. 
Colonies were picked from the plate under sterile conditions, streaked into a 0.5 ml PCR tube 
and sequentially on a new LB Agar plate supplemented with the appropriate antibiotic as a 
selection marker. Primers were designed such that the forward primer annealed in the vector, 
upstream of the insert, and the reverse primer annealed in the insert itself. PCR reactions were 
analysed on a 1% Agarose gel to find the colonies for which a positive PCR result was seen 
under UV illumination. The LB agar plate, where colonies had been streaked, was incubated 
overnight at 37°C, and used on the following day to inoculate cultures for positive colonies 
identified during the screen.  
Reaction set-up for Colony PCR 
 
H2O    10.25 µl 
10 x Euro Taq buffer     2.50 µl 
50 mM MgCl2      1.25 µl 
10 mM dTPs mix     0.50 µl 
2.5 µM FP       5.00 µl 
2.5 µM RP       5.00 µl 
Euro-Taq  
DNA Polymerase    0.50 µl 
Total Volume   50.00 µl 
 
2.2.3.9 Isolation of plasmid DNA from bacteria  
2.2.3.9.1 Small scale isolation – “minipreps”  
 
After identifying positive clones through colony PCR, 10 ml LB cultures (supplemented with 
µg/ml Ampicillin) were inoculated and grown overnight at 37°C with shaking. Plasmid DNA 
was isolated from the bacteria using a High Pure Plasmid isolation Kit (Roche, Mannheim). 
This system is based on an alkaline lysis of cells followed by adsorption of DNA onto special 
glass fibers. DNA was eluted using Tris-HCl buffer and and was aliquot sent for sequencing.  
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2.2.3.9.2 Large scale isolation-“maxipreps” 
 
Large scale preparations of plasmid DNA were carried out using a QIAGEN Plasmid Maxi 
kit. A colony containing the plasmid of choice was used to inoculate 400 ml Super broth 
containing 100 µg/ml Ampicillin, and grown for 12-16 hours at 37°C with shaking. This kit 
too uses alkaline lysis of cells but involves binding of DNA to an anion-exchange resin under 
appropriate pH and low salt conditions. Contaminants are removed using a medium salt wash, 
DNA eluted using high salt buffer followed by precipitation and desalting with isopropanol.  
2.2.3.10 Sequencing of DNA  
 
DNA samples were sent to GATC, (Konstanz) for sequencing. The Sanger dideoxynucleotide 
method (Sanger et al., 1977) was used. BioEdit software was used to analyze the sequences 
obtained.  
2.2.3.11 in vitro synthesis of RNA  
 
cRNA to be injected in X. laevis oocytes was transcribed in vitro using a mMessage 
mMachine SP6 kit (Ambion). It involved the use of a SP6 promotor binding RNA polymerase 
to transcribe RNA using a linear DNA template, after which the DNA template was degraded 
through the action of a DNase. Linearised plasmid (dissolved in DEPC treated H2O) was used 
as template to avoid formation of cRNA molecules that vary in their length, which would 
happen if a circular plasmid were used since RNA polymerase would fall off the template at 
arbitrary points. Reactoins were set up as below:  
 
cRNA Transcription  
Nuclease-free H2O  as required 
10 x Reaction buffer    2 µl 
2 x dNTP   10 µl 
Linearized plasmid  as required 
(1 µg) 
Enzyme mix      2 µl 
Total Volume   20 µl 
Incubated at 37 °C for 2 hours.  
+ 1 µl of DNAse, and incubated at 37 °C for 15 min.  
Then, +30 µl of LiCl and +30 µl Nuclease-free H20 
Incubated overnight at -80°C. 
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DNase was used to degrade the template DNA whereas RNA was precipitated with LiCl. 
After overnight incubation, reactions were centrifuged at 13000 rpm, 4°C for 30 min in a 
microcentrifuge. The pellet was washed once with 70% Ethanol to remove contaminating 
salts, centrifuged and again washed with 100% Ethanol. Pellet was dissolved in 10µl of 
nuclease-free H2O after air drying. RNA concentration was measured with a UV 
spectrophotometer (UVIKON) and an aliquot analyzed on agarose gel to check for integrity 
of RNA.  
2.2.4.1 Isolation of total protein from X. laevis oocytes  
 
Oocytes injected with the desired RNA were collected 3 days after injection in RIPA buffer 
containing Complete™ Protease inhibitor cocktail (Roche, Mannheim). 10 oocytes were 
washed 3-4 times with RIPA buffer before adding to 100 µl of RIPA buffer with protease 
inhibitor. Samples were placed on ice and oocytes crushed manually with the help of a pipette 
tip and by pipetting up and down. Lysed oocytes were maintained on ice for 30 min. while 
vortexing intermittently, after which lysates were centrifuged at 13000 rpm, 4°C for 30 
minutes. The supernatant was pipetted out and placed in a fresh tube, while taking care to 
avoid the frothy top layer. The centrifugation step was repeated two more times and the 
supernatant thus cleared, after which lysates were stored at -20°C.  
2.2.4.2 SDS-PAGE electrophoresis  
 
Proteins can be separated through Polyacrylamide gel electrophoresis (PAGE) according to 
their electrophoretic mobility. Loading buffer and gel contain SDS, an anionic detergent 
which denatures secondary and non-disulfide linked tertiary structures and applies a negative 
charge to each protein. This enables separation based on charge to mass ratio of each protein. 
Before loading protein samples are heated in presence of β-mercaptoethanol, a reducing 
agent, so that any disulfide linkages present in the protein get reduced. PAGE gels are formed 
by polymerization of Acrylamide and N,N’-methylbisacrylamide. The reaction is inititated by 
ammoniumpersulfate (APS) and catalyzed by tetramethylethylenediamide (TEMED). 
Manipulating the polyacrylamide content changes the pore size which influences the degree 
of separation of proteins. The gel itself is made up of two parts - a stacking gel and a running 
gel. Stacking gel contains the loading pockets and has larger pores to concentrate the sample 
Materials and Methods 
 47
before separation, whereas the running gel has smaller pores for dispersion of proteins 
(Laemmli, 1970). Composition of each gel was as described: 
 
Component    Stacking gel    Running gel 
 
H2O :    3.46 ml    3.35 ml 
1M Tris pH 6.8 :  0.63 ml    ---------- 
1.5 M Tris pH 8.8 :  ---------    2.50 ml 
10% SDS :   0.05 ml    0.10 ml 
30 % Acrylamide :  0.83 ml    4.00 ml 
10% APS :   0.05 ml    0.10 ml 
TEMED :   5 µl     6 µl 
 
Prior to loading, protein samples were diluted 1:1 (v/v) with 2 x SDS loading buffer and 
heated at 70°C for 3 minutes. Electrophoresis was carried out at 60 mA constant current for 
75 minutes in SDS gel running buffer till bromophenol blue present in samples ran out of the 
gel.  
 
2.2.4.3 Coomassie staining of proteins 
 
Proteins immobilized in SDS-PAGE gel were detected by Coomassie staining after gel 
electrophoresis. This was done to control loading of similar amounts of protein in different 
samples. SDS-PAGE gels were quickly washed with deionised water after electrophoresis and 
then stained with Coomassie staining solutions for 20 minutes at room temperature. 
Destaining was carried out by incubating in Coomassie destaining solution till bands were 
detectable.  
2.2.4.4 Western blotting 
 
Western blotting is a method for detection of proteins where the samples are immobilized on 
a membrane support. Protein samples are first run on a SDS-PAGE gel, after which they are 
transferred to a membrane such as Polyvinyldifluoride (PVDF) or Nitrocellulose. The 
membrane is subsequently subjected immunochemical analysis whereby antibodies against a 
specific protein or polypeptide are used to detect the band of interest.  
 
Transfer of proteins from SDS-PAGE gel to PVDF membrane was carried out through a 
semi-dry transfer. After electrophoresis, the gel was rinsed 3-4 times with deionised water and 
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incubated in semi-dry transfer for 20 minutes. PVDF membrane was cut to the size of gel and 
activated by dipping in methanol for 30 seconds, and subsequently incubated in semi-dry 
transfer for 20 minutes at RT. 6 pieces of Whatman filter paper were also cut to the size of gel 
and kept in transfer buffer. After lapse of the incubation period, 3 pieces of filter paper were 
laid on the electrode of transfer chamber, while being careful not to trap air bubbles between 
filter papers. The membrane was laid over filter papers, and then slight amount of buffer was 
layered over. The gel was placed on top and then covered with 3 piece of filter paper. Transfer 
was carried out at 15V, 230 mA constant current for 60 minutes. 
 
After transfer, blots were incubated overnight with the blocking solution and subsequently 
incubated with a 1:1000 dilution of primary antibody (α-PfCRT or α-Tubulin ) prepared in 
1% BSA in PBS. Blots were then washed with PBST, 3 times 10 min each, after which they 
were incubated with secondary antibody coupled with POD diluted 1:10000 in blocking 
solution at RT for 30 min, followed by 3 x 10 min. washes with PBST and 1 x 10 min. with 
PBS.  
 
Blots were developed with the help of Enhanced Chemiluminescence kits (ECL). Perodixase 
substrate from the kit was applied to the blot for one minute at RT and then drained 
Peroxidase antibody attached on the blot acts on the substrate and the reaction produces 
luminescenbce, which was used to expose an X-Ray film in a dark room. X-Ray films were 
developed using a Hyperprocessor developing machine (Amersham Pharmacia Biotech).  
2.2.4.5 Stripping western blots 
 
Membranes used for western blotting with one antibody were reused to detect another protein 
such as Tubulin. This was achieved by stripping the blot of the antibody sandwich and 
immunochemical detection was subsequently carried out. After exposure of X-ray films, 
membranes were washed 4 x 10 min with PBS. Stripping was carried out by incubating 
membrane in stripping buffer at 55°C for 30min. Membranes were washed 5 x 10 min with 
PBS after washing, and then blocked overnight with blocking solution. Rest of the 
immunochemistry was carried out subsequently.  
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2.2.5 Xenopus laevis oocytes  
2.2.5.1 Surgical isolation of ovaries from Xenopus laevis frogs 
 
Adult female X. laevis frogs, purchased from NASCO, U.S.A., were anaesthesized with 0.1% 
(w/v) solution of Ethyl 3-amino benzoate methanesulfonate (Sigma, Mannheim) for 15-20 
min. Frogs were then laid on a moist tissue paper placed on ice, and an incision made with a 
scalpel to cut the outer skin. After slitting open the abdominal muscle layer, oocytes lobes 
were pulled out with the help of tweezers. Each cut was individually stitched together and the 
frog was revived by placing in a water tank. A glass support was placed below the frogs so as 
to prevent drowning; the support was removed once frogs’ movement was observed to be 
normal. The following day frogs were returned to the animal facility. Individual frogs were 
operated upto four times, while giving at least 4 weeks recovery time between successive 
operations.  
2.2.5.2 Collagenase treatment  
 
Oocytes are wrapped in a collagenous membrane that envelopes individual oocytes as well as 
oocyte lobes. Oocytes separated from lobes still retain collagen on their surface, which proves 
to be an impediment in injecting RNA. For this purpose, collagenase was enzymatically 
removed using collagenase extracts from Clostridium histolyticum. Collagenase calatalyzes 
hydrolysis of –R-Pro-8-X-Gly-Pro-R- sequence in polypeptides where R is most often a 
neutral amino acid. 
 
Surgically isolated oocytes lobes of X. laevis were manually separated into groups of 8-10 
oocytes in OR2 buffer. After washing 4-5 times with OR2 buffer, 2-3 ml volume of separated 
oocytes were placed in a 50 ml tube and volume made upto 30 ml with OR2. Collagenase I A 
(Sigma, Mannheim) was added to a final concentration of 0.3 FALGPA units/ml, and the 
mixture gently rotated on a vertical shaker at RT. Oocytes were checked for removal of 
collagene after 90, and then at 15 min. intervals. The treatment lasted 2 hours on average, 
after which oocytes were washed 10-15 times with OR2 and 3-5 times with ND96 
(supplemented with Penicillin-Streptomycin and Sodium Pyruvate).  
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2.2.5.3 Selection and culture of X. laevis oocytes 
 
Oocytes endure enzymatic as well as mechanical stress during collagenase treatment, and 
hence many rupture or get apoptotic. Healthy oocytes were, therefore, selected visually under 
microscope and separated from the main batch. These, like the treated oocytes, were 
maintained in ND96 buffer supplemented with Penicillin-Streptomycin and Sodium pyruvate 
at 18°C. Selected oocytes were injected the following day. After injection oocytes were 
checked daily. Apoptotic or demorphed oocytes, as identified by loss of colouration in the 
animal hemisphere or loss of shape, were selected out. ND96 buffer was replaced daily.  
2.2.5.4 Injecting RNA in X. laevis oocytes  
 
In vitro transcribed cRNA was diluted to 0.6 µg/µl final concentration and dispensed into 
aliquots of 3 µl and stored at -80°C. These aliquots were taken out prior to injection. 
Transjector 5246 (Eppendorf, Germany) was used to inject RNA aliquots into collagenase 
treated oocytes. Glass capillaries GB 100 F10 (Scientific products GmbH, Germany) were 
pulled to yield capillaries with a tapered end. These were filled with RNA aliquot to be 
injected and affixed onto a microinjector. The tip of the capillary was broken with the help of 
fine tweezers (Dumont, Switzerland) and the parameters of injector manipulated till a drop of 
50 nL was obtained, as observed under the microscope (LEICA). The drop volume was 
computed by measuring the diameter of drop under 1.6 x magnifications. The injection 
capillary was inserted into individual oocytes lined up in a injection Petri dish with the help of 
manipulator. Oocytes were observed for slight swelling caused by injection, after which the 
capillary was carefully taken out of the oocyte, and the procedure continued. After injection, 
oocytes were maintained in ND96 with Penincillin-Streptomycin and Sodium pyruvate at 
18°C.  
 
2.2.6 Measurement of radioisotope accumulation  
 
X. laevis oocytes injected with the appropriate cRNA were used for uptake experiments 2-3 
days after injection. Experiments were carried out by incubating groups of 10 ooyctes in 2 ml 
tubes containing 200 µl of uptake assay buffer. Uptake assay buffer was ND96 pH 6.0 
containing non-labelled drug and the radioactively labelled form of the drug; the latter was 
used at a final concentration of 50 nM. Oocytes were first washed with ND96 pH 6.0 before 
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adding to the uptake assay buffer. Uptakes were carried out at 25°C, and after the desired 
amount of incubation time, oocytes were taken out add washed 3 times with ice-cold ND96 
pH 6.0 containing only the non-radioactive substrate, in a 24-well cell culture plate. After 
washing, oocytes were individually placed in 2 ml liquid scintillation counting vials 
(Beckman, Germany) and lysed with 200 µl of 5% SDS. Having homogenized the lysed 
oocytes by vortexing, 2 ml of liquid scintillation counting cocktail was added, vials closed 
with screw-caps and vortexed before proceeding to counting. Counting was done with a 
Liquid scintiallation counter (Beckman, Germany) which measured the amount of radioactive 
label incorporated in ocytes in counts per minute (cpm). Using the specific activity of the 
radiolabelled compound and the amount of cold substrate in the uptake buffer, total amount of 
the compound incorporated was calculated in picomoles.  
 
2.2.7 Data analysis 
 
Data were analyzed with Prism 3.0 (GraphPad Software) and SigmaPlot 11.0 
(Systat Software Inc.). Graphs were drawn using SigmaPlot 11.0.  
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3 Results 
 
3.1  X. laevis oocytes as a system to measure CQ transport 
 
PfCRT expressed in X. laevis oocytes has been shown to have saturable Michaelis-Menten 
kinetics for chloroquine transport (Martin et al., 2009a). It was, however, shown in this work 
that PfCRT being a vacuolar membrane protein harbours a number of putative targeting 
motifs in its N and C-termini, which target the protein to cellular compartments other than the 
plasma membrane upon expression in oocytes. The same study showed that mutating the 
putative motifs to alanine allows efficient plasma membrane expression, leading to increased 
accumulation of CQ in oocytes. This approach was used here to express PfCRT in X. laevis 
oocytes. Fig. 3.1 shows in detail the changes made in the terminal portions of PfCRT. The 
motif free form of the protein has been termed PfCRT*.  
 
N-terminus 
              1         10        20        30        40        50 
              |....|....|....|....|....|....|....|....|....|....| 
PfCRT         MKFASKKNNQKNSSKNDERYRELDNLVQEGNGSRLGGGSCLGKCAHVFKLI 
PfCRT*        MKFASKKNNQKNSSKNAERARAADNAAQEGNGSRLGGGSCLGKCAHAAKAA 
 
 
C-terminus 
                   410       420   
              |....|....|....|.... 
PfCRT         NEENEDSEGELTNVDSIITQ 
PfCRT*        NEENADSAGALTNVDSAATQ 
 
Figure 3.1: Mutating putative trafficking motifs in PfCRT.  
Putative membrane trafficking motifs in the N and C termini of PfCRT were mutated to alanine residues 
(highlighted in grey) to ensure targeting to the oocyte plasma membrane. PfCRT refers to the motif-replete form 
whereas PfCRT* is the motif-free version.  
 
Table-1: Differences in the amino acid sequence of PfCRT HB3 and Dd2 alleles 
Amino acid position of mutations in PfCRT 
Resistance Allele Origin 
72 74 75 76 144 160 220 271 326 356 371
CQS HB3 Honduras C M N K A L A Q N I R 
CQR Dd2 Indochina C I E T A L S E S T I 
 
CQS = Chloroquine sensitive, CQR = Chloroquine resistant 
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Figure-3.2: Expression and activity of trafficking motif free PfCRT in PfCRT  
A. Uptake of chloroquine in PfCRT injected oocytes. cRNA for HB3 (motif replete), Dd2 (motif replete), HB3* 
(motif free) and Dd2* (motif free) was injected. Only the motif free PfCRT Dd2* showed significant 
accumulation of CQ as compared to water injected control (*** = p < 0.001). Data are presented as mean ± SEM 
from three independent measurements.  
B. Western blots showing expression of PfCRT alleles in X. laevis oocytes. PfCRT lacking putatitve targeting 
motifs has been shown as PfCRT mut. RBC and P. falciparum Dd2 infected RBC (iRBC) were used as negative 
and positive controls respectively for PfCRT antibody.  
 
 
Yeast-codon optimized PfCRT HB3 and Dd2 coding sequences were cloned in the pSP64T 
vector as described in materials and methods. As for the motif free HB3 and Dd2, these were 
synthesized by GeneART AG and subsequently cloned into pSP64T vector. In vitro RNA to 
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be injected in oocytes was transcribed from these constructs as per the protocol given in 
materials and methods.  
 
CQ accumulation was measured in oocytes injected with both motif free and motif replete 
forms of PfCRT, as a proof of principle (Fig 3.2). Table-1 shows the differences between the 
amino acid sequences of the HB3 (chloroquine sensitive) and Dd2 (chloroquine resistant) 
alleles. X. laevis oocytes were injected with RNA for the HB3 and Dd2 alleles of PfCRT in 
both motif-replete and motif-free forms. Uptake of CQ was measured 3 days post injection in 
pH 6.0 buffer containing 10 µM chloroquine and 50 nM [3H] CQ. Only oocytes injected with 
motif-free Dd2 allele showed significant increase (p < 0.001, t-test) in chloroquine uptake as 
compared to water injected controls. Uptake in case of HB3 injected oocytes was similar to 
control irrespective of the motif-replete or free version (Fig 3.2A). A Western analysis carried 
out to check expression of the injected cRNA verified that in all cases PfCRT was expressed 
(Fig 3.2B). Moreover, the anti-PfCRT antibody identified a band specific to infected 
erythrocytes, and of a similar molecular weight, showing that the protein being expressed in 
oocytes is indeed PfCRT. All PfCRT alleles mentioned hereafter refer to the motif free form.  
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3.2  CQ uptake mediated by PfCRT Dd2 is time dependent,  
saturable and sensitive to verapamil inhibition 
 
To ascertain the dependence of CQ uptake on time, a time-course was carried out as shown in 
Fig 3.3. Oocytes injected with water, PfCRT HB3 and Dd2 were incubated for 3 days after 
injection with 10 µM CQ and 50 nM [3H] CQ at pH 6.0 in groups of 8-10 oocytes. Drug 
accumulation in oocytes was measured at different time points, and plotted as a function of 
time. Data points were fitted using an exponential rise to maximum function. 
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Fig 3.3: Time course of chloroquine uptake in PfCRT injected oocytes.  
Accumulation of chloroquine (CQ) was measured at varying time points for water-injected control (open 
circles), PfCRT HB3 injected (grey-filled circles) and PfCRT Dd2 injected oocytes (black-filled circles). Each 
data point represents mean ± SEM. (n = 3, with 10 oocytes per time point in each experiment).  
 
Fig 3.3 shows that with increasing time, the difference of uptake between PfCRT Dd2 
injected and water injected control oocytes increased. Accumulation in PfCRT HB3 injected 
oocytes was similar to water-injected control oocytes at all time points. Dd2 mediated CQ 
uptake remained linear over time upto 180 minutes.  
 
After measuring the dependence on time, the relationship between uptake and substrate 
concentration was tested (Fig 3.4). Accumulation was measured at 60 minutes time point as 
this lay within the linear phase of CQ uptake, as demonstrated by the time course in Fig 3.3. 
Because PfCRT HB3 injected oocytes did not show increase an CQ accumulation as 
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compared to controls, the substrate dependence was measured only for PfCRT Dd2. Oocytes 
injected with PfCRT Dd2 were incubated for 60 minutes in pH 6.0 buffer containing 
increasing amounts of unlabelled CQ, along with 50 nM of [3H] CQ. Accumulation measured 
in controls was substracted from that in Dd2 injected oocytes, and plotted as a function of the 
substrate concentration (Fig 3.4). Data points were fitted with the Michaelis-Menten equation 
V = Vmax*S/Km+S (Atkins, 2010) where V is the uptake, Vmax is maximum velocity of uptake, 
Km is the Michaelis-Menten constant and S is the substrate concentration. These curves also 
yielded the apparent maximum velocity of uptake Vmax and the Michaelis-Menten constant 
Km. Fitting the points with a modified version of the Michaelis-Menten equation gave 
Vmax/Km values.  
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Fig 3.4: Concentration dependence of chloroquine uptake in PfCRT injected oocytes.  
Accumulation of chloroquine (CQ) measured at increasing concentration for water-injected control 
(open circles), PfCRT HB3 injected (grey-filled circles) and PfCRT Dd2 injected oocytes (black-filled circles), 
and their difference plotted as a function of substrate concenration. Each data point represents mean ± SEM. 
(n = 3, with 10 oocytes per time point in each experiment).  
 
CQ uptake mediated by PfCRT Dd2 initially increased with increasing amounts of CQ, and 
eventually approached saturation (Fig 3.4). Apparent Km and Vmax values of 245 ± 32 µM and 
63 ± 3 picomoles oocyte-1 hour-1 were obtained from the curve fit. These were similar to 
previously measured values for these parameters  (Martin et al., 2009b). A Vmax/Km value of 
0.256 ± 0.022 µl oocyte-1 hour-1 was also obtained.  
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In order to confirm that the CQ accumulation was a result of PfCRT transport activity, uptake 
was inhibited with verapamil, a known chemosensitizer of CQ resistance and a blocker of 
PfCRT (Henry et al., 2006). PfCRT Dd2 injected and water injected control oocytes were 
incubated in pH 6.0 buffer containing 10 µM CQ with 50 nM [3H] CQ. In another group, both 
control and Dd2 oocytes were incubated in a buffer containing the same amount of labelled 
and un-labelled CQ, but supplemented with 100 µM of Verapamil. Each group contained 10 
oocytes and was incubated for 60 minutes in the uptake buffer, after which accumulation was 
measured.  
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Fig 3.5: Inhibition of PfCRT Dd2 mediated CQ transport with Verapamil   
Accumulation of chloroquine (CQ) was measured with 10 µM CQ, in absence (black bars) and presence 
(grey bars) of 100 µM verapamil. Bars represent means ± SEM. from 4 independent experiments with 10 
oocytes per group in each. Stars stand for p-values obtained from a t-test (*** = p < 0.001).  
 
 
Fig 3.5 shows the result of CQ uptake performed in presence of verapamil. Uptake of CQ in 
water injected control oocytes was not influenced by verapamil. PfCRT Dd2 injected oocytes 
accumulated significantly more CQ than controls (p < 0.001, t-test). However, uptake of CQ 
in Dd2 injected oocytes incubated with verapamil was significantly less in comparison to 
oocytes without verapamil (p < 0.001, t-test). This showed that the CQ uptake mediated by 
PfCRT Dd2 is specific and inhibitable with verapamil.  
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3.3 Quinine and quinidine are substrates for mutant 
PfCRT 
 
Time-course, concentration dependence and verapamil inhibition of CQ uptake were carried 
out to establish a PfCRT transport system in X. laevis oocytes, as shown in a previous study 
(Martin et al., 2009b). Having achieved this, the next question was whether other 
aminoquinolines such as quinine (QN) and its stereoisomer quinidine (QD) are also substrates 
of PfCRT mediated drug transport. In order to answer this question, a time-course was first 
performed for quinine and quinidine. Water injected, PfCRT HB3 injected and PfCRT Dd2 
injected oocytes were incubated at room temperature in pH 6.0 buffers with 10 µM of 
unlabelled and 50 nM of [3H]-labelled quinine and quinidine each. Incubation was carried out 
for increasing time points, after which drug accumulation was measured. These time-courses 
are shown in Fig 3.5 (on the following page).  
 
Similar to chloroquine, the accumulation of both QN and QD increased in PfCRT Dd2 
injected oocytes over time, in comparison to water injected and PfCRT HB3 injected oocytes. 
In both cases, uptake was linear upto at least 2 hours. Uptake of both substrates in PfCRT 
HB3 injected oocytes was similar to that for control. This showed that both quinine and 
quinidine are substrates for PfCRT Dd2 mediated transport.  
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Fig 3.6: Time course of quinine and quinidine uptake in PfCRT injected oocytes.  
A. Accumulation of quinine (QN) measured at varying time points for water-injected control (open circles), 
PfCRT HB3 injected (grey-filled circles) and PfCRT Dd2 injected oocytes (black-filled circles). Each data point 
represents mean ± SEM. (n = 3, with 10 oocytes per time point in each experiment).  
B. Uptake of quinidine (QD) measured in water-injected control (open circles), PfCRT HB3 (grey circles) and 
PfCRT Dd2 (black filled circles) injected oocytes. Data represents mean ± SEM. from 3 independent 
experiments where 10 oocytes per time point were used.  
 
The next step was to see if quinine and quinidine accumulation was saturable or not. For this 
purpose, water injected control oocytes and PfCRT Dd2 injected oocytes were incubated with 
increasing amounts of unlabelled QN and QD, along with 50 nM each of [3H]-labelled QN 
and QD. This was carried out at room temperature in pH 6.0 buffer. Accumulation was 
measured at 60 minutes of incubation as this time point fell within the linear phase of uptake.  
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Fig. 3.7: Substrate dependence of QN and QD uptake in PfCRT injected oocytes. 
Difference in uptake between water-injected control oocytes and PfCRT Dd2 injected oocytes has been plotted 
as a function of substrate concentration. Each point represents mean ± SEM from 3 independent experiments, 
where 8-10 oocytes were used per data point in each experiment.  
 
PfCRT Dd2 mediated QN and QD transport was plotted as a function of substrate 
concentration, after substracting the control values from those for PfCRT Dd2 (Fig 3.7). Data 
points were fitted using a Michaelis-Menten equation. Accumulation of both QN and QD 
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increased with increasing substrate concentration, culminating in a plateau phase. This was 
indicative of saturation of transport by increasing QN and QD concentrations. PfCRT Dd2 
showed transport of QN and QD quite similar to that for CQ, thus indicating that PfCRT is 
also a carrier for these two substrates.  
 
Curve fitting yielded kinetic parameters which have been summarized below, along with 
those for obtained for CQ transport:  
 
Table-2: Apparent maximum velocity, Michaelis-Menten constant and Vmax/Km for    
chloroquine, quinine and quinidine transport  
Apparent Vmax Apparent Km Substrate PfCRT 
(pmol/oocyte/hr) (µM) 
Apparent 
Vmax/ Km  
Goodness 
of fit (R2) 
Chloroquine Dd2 63  ± 3 245  ± 34 
 
0.256 ± 0.022 
 
0.9888 
Quinine Dd2 14.53  ± 0.94 31.4  ± 5.4 
 
0.509 ± 0.051 
 
0.9936 
Quinidine Dd2 12.65  ± 0.55 21.3  ± 2.9 
 
0.560 ± 0.071 
 
0.9954 
 
 
To check for inhibition of QN accumulation with verapamil, oocytes were incubated with and 
without 100 µM Verapamil. The result of such an experiment is shown in Fig 3.8.  
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Fig. 3.8: Inhibition of QN uptake with Verapamil 
Bars represent accumulation of 10 µM QN in oocytes, with 100 µM Verapamil (grey bars) and without 
verapamil (black bars). Each bar represents mean ± SEM. from 2 independent experiments, where 8-10 oocytes 
were used per group.  (*** = p < 0.001).  
 
It is evident from Fig 3.8 that accumulation of verapamil in Dd2 and GB4 PfCRT injected 
oocytes decreased significantly (p < 0.001, t-test) as compared to oocytes without verapamil. 
Uptake in water injected control oocytes remained unaffected. Thus, similar to CQ, PfCRT 
mediated QN transport is sensitive to verapamil.  
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3.4 Naturally occurring mutant pfcrt alleles transport CQ 
 
How does CQ transport by PfCRT compare to that by other mutant pfcrt alleles? In order to 
answer this question, five other variants of mutant pfcrt were cloned in the oocyte expression 
vector pSP64T. These were the, 7G8 (Brazil), Ecu1110 (Ecuador), Ph1 & Ph2 (Phillippines) 
and GB4 (Ghana) alleles (Chen et al., 2003, Fidock et al., 2000, Sa et al., 2009). Countries 
indicated in brackets stand for the places from which these strains had been isolated. They 
represent distinct origins of chloroquine resistance, and the differences in amino acid 
sequence they encode for are summarized in table-3.  
 
Table-3: Mutant pfcrt variants from different geographical origins 
Amino acid position of mutations in PfCRT 
Allele Origin 
72 74 75 76 144 160 220 271 326 356 371 
Dd2 South-east asia C I E T A L S E S T I 
GB4 S.E.Asia/Africa C I E T A L S E N I I 
Ecu1110 South-america C M N T A L S Q D L R 
7G8 South-america S M N T A L S Q D L R 
Ph1 Phillippines C M N T T Y A Q D I R 
Ph2 Phillippines S M N T T Y A Q D I R 
 
Yeast-codon optimized coding sequences for PfCRT 7G8 and Ph1 were synthesized by 
GeneART AG and subsequently cloned into pSP64T vector. Ecu1110 and Ph2 coding 
sequences were constructed by mutating cysteine at position 72 to a serine. Oocytes were 
injected with mRNA transcribed in vitro from these plasmids. PfCRT Dd2 injected and water 
injected oocytes served as positive and negative controls respectively. 3 days after injection, 
oocytes injected with all these alleles were subjected to a CQ uptake experiment. Oocytes 
were incubated for 60 minutes at room temperature in pH 6.0 buffer containing 10 µM CQ 
and 50 nM [3H CQ]. Results of this CQ screen have been shown in Fig 3.9.  
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Fig 3.9: Screening naturally occurring mutant pfcrt alleles for chloroquine uptake  
Oocytes injected with different PfCRT alleles were checked for chloroquine (CQ) uptake after one hour 
incubation in pH 6.0 buffer containing 10 µM unlabelled and 50 nM [3H]CQ respectively. The dotted line in the 
middle represents the mean uptake obtained in water injected control oocytes. Data represents means ± SEM. 
from 4-5 independent experiments with 10 oocytes per allele in each. (*** = p < 0.001).  
 
Fig 3.9 shows that injection of all the six mutant PfCRT variants led to increased uptake of 
CQ in comparison to water injected control oocytes (p < 0.001, t-test). The South-East 
Asian/African alleles (Dd2, GB4) accumulated significantly more CQ than did oocytes 
injected with South-American (7G8, Ecu1110) or Phillipine (Ph1, Ph2) alleles (p < 0.001, t-
test). Thus, this experiment demonstrated that different alleles of mutant pfcrt can mediate CQ 
uptake upon expression in oocytes. However, the differences in the levels of accumulation 
suggest that differences in the mutated amino acid residues may influence the kinetics of CQ 
transport. To investigate this point further, concentration dependence of CQ uptake was 
measured for these alleles. The method employed was similar to that for PfCRT Dd2, where 
accumulation of CQ was measured at increasing concentrations of unlabelled CQ. Uptake was 
measured at the 60 minut incubation time point, and values obtained for water injected control 
oocytes were substracted from those for PfCRT injected oocytes. The resultant accumulation 
values were plotted as a function of the CQ concentration, and have been featured in Fig 3.19 
and 3.11. Data points were fitted using the Michaelis-Menten equation.  
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Fig 3.10: Dependence of CQ uptake on substrate concentration for mutant PfCRT alleles  
CQ accumulation in water injected control oocytes was substrated from that in PfCRT injected oocytes, and 
plotted against concentration. Data represents means ± SEM from 3 independent experiments with 10 oocytes 
per allele per data point in each.  
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Fig 3.11: Dependence of CQ uptake on substrate concentration for PfCRT GB4 
CQ accumulation as a function of concentration, plotted for PfCRT GB4 after background substraction.  Data 
represents means ± SEM. from 3 independent determinations with 10 oocytes per data point in each.  
 
Curves in Fig. 3.10 and 3.11 yielded apparent Vmax, Km and Vmax/Km values. These, along 
with those obtained earlier for PfCRT Dd2, are shown in Table-3 below.  
 
 
Table-4: Apparent Vmax, Km and Vmax/Km obtained for mutant PfCRT. 
Apparent Apparent Apparent 
CQ Vmax           
[pmol/oocyte/h]  
 CQ Km        
[µM]  Vmax/Km for CQ 
Allele 
      
Goodness of 
fit (R2) 
Dd2 63 ± 3 245 ± 32 0.256  ± 0.022 0.9902 
GB4 120 ± 10 763 ± 118 0.157  ± 0.013 0.9926 
Ecu1110 45 ± 4 231 ± 40 0.197  ± 0.018 0.9943 
7G8 11.5 ± 0.6 141 ± 16 0.081  ± 0.005 0.9941 
Ph1 21.5  ± 1.4 182 ±  26 0.118  ± 0.001 0.9948 
Ph2 11  ± 1 76 ±  23 0.144  ± 0.031 0.9746 
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Km is independent of the amount of carrier protein, whereas Vmax is not (Atkins, 2010).The 
apparent Michaelis-Menten constants for different PfCRT variants could therefore be 
compared with a t-test without taking into account individual expression level of these alleles 
in the oocyte. This showed that Dd2 and GB4 (p < 0.01), Ph1 and Ph2 (p < 0.05), Ecu1110 
and Ph2 (p < 0.05) Km values were significantly different. GB4 Km was found to be 
significantly different for that of Ecu1110 (p < 0.001), 7G8 (p < 0.01), Ph1 (p < 0.001) and 
Ph2 (p < 0.001). While the same result was not seen when Ecu1110 and 7G8 PfCRT were 
compared (p = 0.1049), this may have been due to the comparatively higher experimentally 
error in the 7G8 measurements. Ecu1110 and Ph1 too did not differ significantly in their CQ 
Km. These Km comparisons highlight that single (as between Ph1 and Ph2), or at the most two 
amino acid substitutions (as between Dd2 and GB4) could significantly alter the half-
saturation constant for CQ. The significant difference in Km between Ecu1110 & Ph2 and that 
between Ph1 & Ph2, but not between Ph1 & Ecu1110 and 7G8 & Ph2 suggests that having 
the amino residue serine at position 72 implies a PfCRT with lower Km for CQ, as compared 
to a PfCRT with cysteine at the same position.  
 
To confirm that CQ accumulation observed in Fig. 3.9 was indeed because of transport 
through PfCRT, a verapamil inhibition experiment was performed. This was carried out in a 
similar way as done earlier for PfCRT Dd2. Oocytes injected with a particular allele were 
divided into two groups and incubated for 60 minutes in the uptake assay buffer. Both groups 
contained 10 µM of unlabelled and 50 nM of 3H CQ, whereas only had 100 µM Verapamil in 
addition. Water injected and PfCRT Dd2 injected oocytes were used as negative and positive 
controls respectively. The results obtained are shown in Fig 3.12.  
 
 
 
 
Results 
 68
 A 
Wa
ter Dd
2
GB
4
Ec
u1
11
0
7G
8
Ph
1
Ph
2
C
Q
 u
pt
ak
e 
(p
m
ol
/o
oc
yt
e/
h)
0
3
6
*** ****** *
*
***
 
B 
Wa
ter Dd
2
GB
4
Ec
u1
11
0
7G
8
Ph
1
Ph
2
C
Q
 u
pt
ak
e 
(n
or
m
al
iz
ed
)
0
60
120
 
Fig 3.12: Inhibition of CQ uptake in PfCRT injected oocytes with Verapamil  
A. CQ accumulation in oocytes was measured with (grey bars) and without (black bars) 100 µM Verapamil. 
Stars represent p-values from t-tests performed to measure significance of the Verapamil induced decrease in CQ 
uptake (* = p<0.05, *** = p<0.001). Bars represent means ± SEM. from 4 independent experiments with 8-10 
oocytes in each.  
B. shows data from Panel A in a normalized format. For each group, uptake with CQ alone has been normalized 
to converted to 100% (black bars). CQ uptake in presence of verapamil (grey bars) is thus expressed as the 
fraction of uptake without Verapamil.  
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Fig 3.12A shows that Verapamil inhibited CQ uptake in PfCRT injected oocytes, whereas in 
water injected control oocytes it did not have an effect. This is consistent with uptake in 
control being a result of CQ diffusing through the oocyte plasma membrane. The elevated 
uptake in PfCRT injected oocytes, on the other hand, was mediated by PfCRT and could 
therefore be inhibited. However, the significance of this reduction varied amongst PfCRT 
variants. Inhibition was highly significant (p < 0.001, t-test) for the Dd2, GB4, 7G8 and Ph2 
alleles, but only slightly significant (p < 0.05, t-test) for PfCRT Ecu1110 and Ph1. To 
highlight these differences, data from Panel A of Fig. 3.12 have been expressed as percentage 
of uptake with CQ alone in Fig. 3.12B. For each group of each injected oocytes, accumulation 
with CQ alone is shown as 100%. The inhibition of CQ uptake by verapamil is thus the 
percentage of uptake with CQ alone. It is clear that for the Dd2 and GB4 alleles uptake with 
verapamil was about 25-30% of uptake without verapamil. This figure was around 75 % for 
Ecu1110, 7G8, Ph1 and Ph2 PfCRT. Thus, the South-American and Phillipine PfCRT 
variants showed only slight reduction in CQ uptake when verapamil was used, whereas such a 
reduction in the South-East Asian/African PfCRT was much more pronounced.  
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3.5 Mutant PfCRT with only three amino acid changes can 
still transport CQ  
 
The data presented so far argue that mutant PfCRT alleles can transport CQ, although with 
different kinetic properties. On the other hand wild-type PfCRT does not lead to accumulation 
of CQ when expressed in oocytes. So what then is the minimum change required to convert 
the wild-type PfCRT into a mutant PfCRT capable of CQ uptake? A look at Table-2 shows 
that both Ph1 and Ecu1110 alleles are mutated at only 4 positions in comparison to the wild-
type, although only two of them, namely K76T and D326N are present in both. Replacing the 
mutated residues with wild-type amino acids would show which of the substitutions are 
necessary for CQ transport. The Ecu1110 was chosen for this purpose because the 
susbtitutions it contains are found more commonly among mutant pfcrt than those from Ph1. 
The constructs that were used in this experiment have been shown in Table-5.  
 
Table-5: Single amino acid replacement constructs made with PfCRT HB3 and Ecu1110. 
Residues shaded that differ from the wild-type PfCRT HB3 have been shaded in grey.  
 
Amino acid position of mutations in PfCRT 
PfCRT 
72 74 75 76 144 160 220 271 326 356 371 
HB3 C M N K A L A Q N I R 
HB3K76T C M N T A L A Q N I R 
Ecu1110 C M N T A L S Q D L R 
Ecu1110T76K C M N K A L S Q D L R 
Ecu1110S220A C M N T A L A Q D L R 
Ecu1110D326N C M N T A L S Q N L R 
Ecu1110L356I C M N T A L S Q D I R 
 
 
Mutant constructs shown above were synthesized by megaprimer synthesis method, and 
cloned into the pSP64T vector. PfCRT HB3, HB3K76T and Dd2T76Khave earlier been shown 
not to transport CQ (Martin et al., 2009b). Thus, only the lysine to threonine change cannot 
account for CQ transport even if it is necessary. HB3K76T and Ecu1110T76K were hence used as 
negative controls, whereas Ecu1110 functioned as a positive control. Uptake in oocytes 
injected with PfCRT Ecu1110S220A, Ecu1110D326N and Ecu1110L356I was compared to those 
injected with Ecu1110. In each case, one amino acid had been mutated back to the wild-type 
counterpart, thus creating a PfCRT with only 2 more mutations apart from K76T.  
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Fig 3.13: Uptake of chloroquine in PfCT HB3 and Ecu1110 mutant constructs 
Data represent means with SEM obtained from 3 independent accumulation experiments where 10 oocytes per 
group were used. Stars represent p-values from t-test (*** = p<0.001).  
 
 
Fig 3.13 features the result of an accumulation experiment performed with 10 µM of CQ. It 
shows that oocytes injected with PfCRT Ecu1110 accumulated significantly more CQ than 
those injected with water (i.e. control) or HB3K76T. The same figure also shows that 
introduction of T76K, D326N and L356I substitutions reduced CQ uptake. This reduction was 
to the level of water injected control oocytes in case of T76K, but not as much for D326N or 
L356I. In each case, reduction in comparison to Ecu1110 was significant (t-test, p < 0.001). 
Ecu1110S220A on the other hand showed no significant difference in CQ accumulation with 
reference to Ecu1110. It can be concluded from this experiment that only 3 amino acid 
substitutions – K76T, D326N and L356I can still account for CQ uptake in oocytes.  
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3.6 PfCRT mutations influence transport of quinine and 
quinidine 
 
Experiments listed previously establish that mutant PfCRT alleles had saturable kinetics for 
CQ accumulation. Of these, PfCRT Dd2 showed accumulation of QN and QD that could be 
saturated and inihibited. In that case, how do other mutant pfcrt alleles fare in relation to QN 
and QD transport? To answer this question, an uptake screen for QN and QD was carried out. 
The results of such a screen have been shown in Fig 3.12. for which both QN and QD were 
used individually at a concentration of 10 µM along with 50 nM of [3H] labelled drug. Drug 
accumulation at 60 minutes time point was measured.  
 
Fig 3.14A indicates that oocytes injected with the South American and Philippine isolates 
namely Ecu1110, 7G8, Ph1 and Ph2 accumulated similar QN and QD as compared to water 
injected controls. PfCRT Dd2 and GB4, on the contrary, took up significantly more 
(p < 0.001, t-test) substrate than the aforementioned alleles, as well as water-controls. QN and 
QD uptake for PfCRT GB4 were significantly different from each other whereas no such 
difference was observed in case of PfCRT Dd2. Fig. 3.14B shows the fraction of uptake 
corresponding to PfCRT alone, which was obtained by substracting control values from 
PfCRT injected oocytes, corresponding to the data in Fig. 3.14A. Uptake of QN between Dd2 
and GB4, and that of QN and QD for GB4 were compared with a t-test, which yielded a p-
value of p<0.05. Thus, the mutations present in Dd2, but absent in GB4, seem to have a 
positive effect on quinine uptake, since quinidine uptake between Dd2 and GB4 was similar.  
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Fig 3.14: Screening pfcrt alleles for quinine and quinidine uptake  
A. Oocytes injected with different PfCRT alleles were checked for quinine (QN) and quinidine (QD) uptake 
Water injected oocytes were used as control.. Data represents means ± SEM. from 3-4 independent experiments 
with 10 oocytes per allele in each. Stars indicate p-values obtained from a t-test performed  to measure the 
significance of uptake (*** = p < 0.001). Black bars represent QN uptake whereas grey bars stand for QD.  
B. QN and QD uptake mediated by PfCRT Dd2 and GB4. Accumulation of QN and QD obtained for controls 
was substracted from values of uptake in Dd2 and GB4 injected oocytes. Data represents means ± SEM. Black 
and grey bars stand for QN and QD respectively. Star shows p-value corresponding to a test (* = p<0.05).  
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Data featured in Fig 3.14 suggests that mutations influence the substrate specificity of PfCRT 
mediated transport. A look at Table-3 indicates that many differences underly the set of 
mutations harboured by pfcrt alleles. But could single amino acid replacements influence the 
ability of PfCRT to transport different quinolines? For this purpose, attention was focused on 
two particular amino acid substitutions found in mutant pfcrt – A220S and N326D. The 
change from alanine to serine at position 220 (A220S) has been observed in all pfcrt isolates 
sequenced so far except in those originating in Philippines such as Ph1 and Ph2 On the 
contrary they have two other substitutions unique to the Philippine variants – A144T and 
L160Y. It is therefore possible that these are in some way compensating for the lack of 
A220S (Bray et al., 2005, Chen et al., 2003). Another interesting change is at position 326, 
where arginine residue at position 326 in the wild-type pfcrt gets replaced by either a serine 
(N326S) or aspartate (N326D). This particular variation also depends on the geographical 
origin of the isolate, in that South-East Asian/African alleles have N362S as against the south 
American, papua new guinea and Philippine isolates which harbour the N326D replacement 
(Cooper et al., 2005). In order to understand how they may influence quinoline transport, two 
mutants were constructed in the Dd2 background by megaprimer synthesis method and their 
coding sequenced cloned into pSP64T vector. One of these was a PfCRT Dd2S220A where the 
serine was mutated back to alanine. Another construct was a PfCRT Dd2S326D where serine at 
position 326 was replaced by an aspartate. These have been shown in Table-6.  
 
Table-6: Single amino acid replacements in PfCRT Dd2 
Amino acid position of mutations in PfCRT 
Allele 
72 74 75 76 144 160 220 271 326 356 371 
Dd2 C I E T A L S E S T I 
Dd2S220A C I E T A L A E S T I 
Dd2S326D C I E T A L S E D T I 
 
 
These two constructs were compared to PfCRT Dd2 for their ability to transport CQ, QN and 
QD. Results from such a comparison have been shown in Fig 3.15.  
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Fig 3.15: Accumulation of chloroquine, quinine and quinidine in PfCRT Dd2 mutants  
A. Chloroquine (CQ) uptake mediated byPfCRT Dd2 mutant constructs, with water injected oocytes as negative 
control. Both black (10 µM CQ) and grey (10 µM CQ+100 µM Verapamil) bars represent means ± SEM. from 4 
independent experiments. (*** = p < 0.001, t-test).  
B. Uptake with 10 µM each of quinine (black bars) and quinidine (grey bars). Data are means means ± SEM 
from 4 independent determeniations with 8-10 oocytes per group in each experiment. 
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Fig 3.15A shows accumulation of CQ measured at a concentration of 10 µM and 60 minutes 
of incubation. PfCRT Dd2 and water injected oocytes were used as positive and negative 
controls respectively. It shows that oocytes expressing PfCRT Dd2 mediated significant 
accumulation of CQ as compared to water injected controls (p < 0.001, t-test). CQ uptake was 
not influenced by introduction of the S220A mutation in Dd2. The S236D substitution, 
however, led to a significant reduction in CQ uptake as compared to the Dd2 positive control 
(p < 0.001, t-test). These mutations did not affect verapamil inhibition, as verapamil caused a 
significant reduction (p < 0.001 for all, t-test). of CQ uptake for each PfCRT. Fig 3.14B 
demonstrates that that uptake of QN and QD in Dd2 and Dd2S220A injected oocytes was 
significantly higher than in water injected controls, but not in oocytes injected with Dd2S326D. 
The reduction in QN and QD accumulation seen on introduction of the S326D replacement 
was significant (p < 0.001, t-test). Thus, QN and QD transport mediated by PfCRT Dd2 was 
abrogated by the S326D replacement but not by the S220A mutation. Since both the Dd2 
mutant constructs showed accumulation of CQ, a dose response curve was plotted in order to 
measure the Michaelis-Menten constant. This has been shown in Fig 3.16. The procedure 
followed was similar to that for other alleles described in previous sections. 
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Fig 3.16: Substrate dependence of chloroquine upake for PfCRT Dd2S220A and Dd2S326D  
Graph shows difference in uptake between PfCRT injected and water injected oocytes was plotted as a function 
of concentration. Data points are means means ± SEM from 3 independent determinations with 8-10 oocytes per 
group in each experiment. 
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Difference of uptake between PfCRT injected and water injected oocytes has been plotted as a 
function of chloroquine concentration in Fig 3.16. Data points were fitted with a hyperbolic 
Michaelis-Menten equation, as done for other PfCRT alleles. Vmax, Km and Vmax/Km values 
obtained from the same are shown below in Table-8.  
 
 
Table-7: Apparent Vmax and Km for PfCRT Dd2 replacement mutants 
PfCRT R2 
Apparent 
 CQ Km     
[µM]  
Apparent 
CQ Vmax        
[pmol/oocyte/h] 
Apparent 
Vmax/Km for 
CQ 
Dd2S220A 0.9995 172 ± 8 51.5 ± 1 0.299 ± 0.008 
Dd2S326D 0.9378 45 ± 21 11.7 ± 1.5 0.259 ± 0.097 
 
 
Comparing the Km values for Dd2 to those mentioned in Table-8 showed that the S220A 
replacement did not lead to a significant change in the Km whereas the S326D change caused 
a significant decrease in the Km (p < 0.01, t-test).  
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3.7 Western blot shows expression of PfCRT alleles in 
oocytes 
 
Fig 3.1 shown earlier confirmed that X. laevis oocytes express a full-length PfCRT protein 
upon injection with the appropriate RNA. This figure also confirmed that the PfCRT* (HB3 
and Dd2) version is recognized by an antibody raised against PfCRT. But are all alleles used 
in this study expressed in oocytes to the same level? To confirm this, a Western blot analysis 
was carried out using oocytes injected with all the PfCRT constructs described in previous 
sections. Oocytes were collected 3 days after injection with 30 ng of RNA for each variant 
and total cell lysates prepared as per the method described in the materials and methods 
section. This blot is shown below in Fig 3.16.  
KDa
36
36
36
Control HB3    Dd2    GB4     Ecu      7G8       Ph1    Ph2    Dd2S220A
55
Control HB3K76T Dd2   Dd2S326D
55
55
T7
6K S2
20A
D3
26N L3
56
I
No
rm
al
PfCRT
PfCRT Ecu1110
PfCRT
α-PfCRT
α-Tubulin
α-PfCRT
α-Tubulin
α-PfCRT
α-Tubulin
 
 
Fig 3.17: Western blot showing expression of PfCRT variants.  
10 µl of total cell lysates prepared from PfCRT injected oocytes and water injected oocytes (control) were 
electrophoresed on a 12% agarose gel, and subsequently transferred onto a membrane support to 
immunochemically detect expression of PfCRT. Ant-tubulin antibody was used as a loading control.  
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Fig 3.17 shows that proteins migrating around 36 KDa were detected with an anti-PfCRT 
antibody in each lane were PfCRT injected oocyte lysates were run. The molecular size is 
close to the predicted molecular weight of full length PfCRT which is 45 kDa. No protein 
could be detected in control lysates prepared from water injected oocytes. This shows that the 
signal is specific to PfCRT and that each PfCRT variant gets expressed upon injection of the 
corresponding RNA in oocytes. After detecting PfCRT, the same membrane was stripped of 
the antibodies. This was followed by use of an anti-alpha tubulin antibody to detect Tubulin in 
the oocyte lysates. With this procedure a band co-migrating with the marker at 55 KDa was 
detected in each lysate, including in the control samples. This is in order because tubulin is a 
constitutive protein of the oocyte and hence should be detectable in all the lysates. Amongst 
these, it appears that the signal for PfCRT Ph2 and Ecu1110 is stronger than that for Ph1 and 
Ecu1110 respectively. This allows the use of tubulin as a loading control for the oocyte 
lysates. A visual comparison of the band intensity for the HB3, Dd2, GB4, Ecu1110, 7G8, 
Ph1, Ph2 and Dd2S220A bands suggests differences in expression, when the tubulin loading 
control is taken into account. Amongst HB3K76T, Dd2 and Dd2S220A samples, the tubulin band 
intensity varies only slightly. As for the PfCRT bands for these samples, only the Dd2S326D 
band appears a little smaller than the Dd2 signal, suggesting a potential difference in the 
expression of these alleles. In the panel with Ecu1110 mutants, the Ecu1110T76K sample 
shows a signal substantially weaker than other lysates on the same blot. However, the normal 
Ecu1110 as well as other three mutants had similar signals for both the PfCRT and the 
Tubulin antibodies. Of the oocytes that were used to prepared the lysates, 10 oocytes for each 
group were employed for an accumulation experiment with 10 µM CQ, the result for which 
did not differ from the screens features in previous sections.  
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4  Discussion 
 
Three questions were raised about PfCRT mediated drug transport in this work– i) Is PfCRT a 
carrier of substrates other than chloroquine ii) Do mutant pfcrt alleles differ in their transport 
of quinolines? and iii) With reference to drug transport, what role is played by amino acid 
substitutions in PfCRT? It was attempted to answer these by expressing a number of naturally 
occurring and laboratory constructed PfCRT alleles in Xenopous laevis oocytes. A Western 
blot analysis confirmed the successful expression of individual PfCRT variants. 
Accumulation experiments performed for chloroquine (CQ), quinine (QN) and quinidine 
(QD) showed that PfCRT corresponding to distinct geographical origins transports CQ. While 
PfCRT Dd2 showed carrier-like transport of QN and QD, not all alleles expressed as part of 
this study presented evidence of QN and QD transport functions. Amino acid substitutions at 
positions 72, 326 and 356 were shown to influence quinoline transport, and only three amino 
acid replacements in the wild-type PfCRT were sufficient for CQ transport. 
 
4.1 PfCRT as a transporter of CQ, QN and QD  
 
While CQ resistant malaria has been linked to mutant pfcrt  (Lakshmanan et al., 2005, Fidock 
et al., 2000, Sidhu et al., 2002), a genetic analysis of QN resistance (QNR) in P. falciparum 
parasites also identified its involvement in QNR (Ferdig et al., 2004). pfcrt polymorphisms 
have also been associated with reduced QN accumulation in P. falciparum parasites (Sanchez 
et al., 2008b), as well as to stereospecific responses to QN and QD (Cooper et al., 2002, 
Cooper et al., 2007).  Kinetics of CQ accumulation in chloroquine sensitive (CQS) and 
chloroquine resistant (CQR) parasites have pointed to PfCRT being a carrier of CQ (Sanchez 
et al., 2005, Sanchez et al., 2004, Sanchez et al., 2007a). It was therefore natural to examine if 
PfCRT can independently transport CQ, QN and QD. Through heterologous expression of 
PfCRT in Xenopus laevis oocytes, a PfCRT mediated, verapamil sensitive and saturable 
uptake of CQ has been demonstrated (Martin et al., 2009b). The same publication also 
showed inhibition of PfCRT Dd2 mediated CQ uptake with a large number of compounds, 
including QN and QD. However, the authors of this study did not present any direct evidence 
of QN and QD transport by PfCRT. The uptake of QN and QD in PfCRT Dd2 expressing 
oocytes, shown as part of this study, directly links PfCRT to transport of these two 
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compounds. Transport of QN from the extracellular buffer to the oocyte cytosol indicates a 
transport from vacuole to cytosol in case of the parasites. PfCRT associated QN transport thus 
suggests removal of QN from the vacuole, and fits into a mechanism for QNR where removal 
of QN from its purpoted target can lead to decreased QN sensitivity.  
 
Time courses for CQ, QN and QD (Fig 3.3, 3.6) showed that uptake of QN and QD at 60 
minutes was higher than that for CQ in water injected control oocytes, even though 10 µM of 
each compound was used. This difference can be explained by protonation and solubility of 
these compounds, which have been described in Table-8.  
 
Table-8: Protonation state and distribution co-efficient for quinoline compounds 
% of total amount 
protonated at pH 6.0    Compound 
Non- Di- Mono- 
Log P Log D at pH 6.0 
Chloroquine 0.00005 99.20 0.79 4.72 -1.84 
Quinine 0.26 0 99.74 3.17 0.58 
Quinidine 0.26 0 99.74 2.84 0.26 
 
Protonation values given in Table-8 have been calculated from the Handerson-Hasselbach 
equation using pKa values for CQ, QN and QD, whereas the distribution co-efficient Log D 
has been calculated from the partition co-efficient Log P values and the equation describing 
relationship between Log P, pH and pKa (Sanchez et al., 2007b, Warhurst et al., 2003). Log D 
describes the solubility of a compound in an octanol/water suspension at a particular pH. By 
definition, a Log D value close to zero describes equal preference between octanol and water, 
whereas negative and positive values describe a tendency for the aqeous and alcohol phases 
respectively. It is evident from Table-6 that both QN and QD are only mono-protonated at pH 
6.0 and are more hydrophobic than CQ which is diprotonated and strongly hydrophilic. This 
explains the difference in background uptake levels of CQ, QN and QD in oocytes.  
 
Similar to CQ, QN and QD transport through PfCRT Dd2 was found to approach saturation 
when substrate concentration was increased (Fig 3.4, 3.7). These, along with the verapamil 
inhibition data (Fig 3.5, 3.8), point towards a carrier-based transport as the likely mechanism 
for QN and QD accumulation. The mean apparent Km values obtained for QN and QD were 
much lower than that for CQ. Thus, saturation of the carrier occurs at a much lower 
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concentration for QN and QD than for CQ, indicating that the affinity of PfCRT Dd2 for QN 
and QD may be higher than that for CQ. Kinetics for transport of QN and that for its 
stereoisomer QD did not differ (Fig 3.7). Another kinetic parameter, namely Vmax/Km, 
represents the rate constant of the transport process at substrate concentration far less than the 
Km. These were measured to be 0.509 ± 0.051 µl oocyte-1 hour-1 for QN, 0.560 ± 0.071 for QD 
and 0.256 ± 0.022 for CQ. Since all three measurements were for PfCRT Dd2 and were 
repeated independently a number of times, it could be assumed that expression levels were 
similar between measurements for the three drugs. In that case, taking ratios of apparent 
Vmax/Km for the different drugs gives the ratio of the efficiency of transport for each 
compound, where efficiency ε = Vmax / Km * Eo (Atkins, 2010). Such a ratio for QN/CQ is 
1.988 whereas that for QN/QD is 2.18, suggesting that efficiency of QN and QD transport by 
PfCRT Dd2 is twice that for CQ. As indicated by Table-8, QN and QD carry a single positive 
charge at pH 6.0 whereas a molecule of CQ carries two. This means that under the conditions 
of measurement, the net displacement of charge remained the same for these three quinolines. 
As for the binding sites for CQ and QN/QD, the data presented here do not allow any 
speculation in that regard. Measurement of CQ transport in the presence of QN, and vice-
versa, would throw more light on the nature of CQ and QN/QD binding sites in PfCRT. 
Concerning stereoisomerism between QN and QD, kinetics for PfCRT Dd2 linked transport 
of these compounds did not seem to differ (Fig 3.7).  
 
Apart from the pfcrt locus on Chromosome 7 of P. falciparum, two other polymorphic loci 
have been identified with a possible role in QNR. These include the transporters Pfmdr1 and 
PfNHE1(Ferdig et al., 2004). pfmdr1 mutations are known to be associated with QNR (Reed 
et al., 2000, Sidhu et al., 2005) and QN is amongst the substrates transported by Pfmdr1 
(Sanchez et al., 2008a, Rohrbach et al., 2006). QN gets pumped into the food vacuole by the 
action of Pfmdr1, but it has been shown that the N1042D mutation in this protein abrogrates 
QN transport (Rohrbach et al., 2006) and decreases IC50 values for QN in parasites (Sidhu et 
al., 2005). This is in accordance with the observed QN transport by PfCRT, as reducing entry 
of QN into the food vacuole as well as increasing its efflux from this organelle can both 
contribute to the QNR phenotype. As for PfNHE, it has been proposed that polymorphisms in 
this sodium proton exchanger contribute to an altered cytosolic pH, which in turn influences 
QNR (Bennett et al., 2007). While the exact involvement of PfNHE in QNR is not yet fully 
understood, it cannot be ruled out that QNR is a complex phenomenon involving factors other 
than mutant pfcrt.  
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4.2  Influence of pfcrt polymorphisms on drug transport  
 
Mutant pfcrt allele exhibits polymorphism, and a number of combinations of amino acid 
substitutions are found to occur in pfcrt harboured by CQR P. falciparum strains (Cooper et 
al., 2005). This raised the question that if the mutant Dd2 allele can transport CQ, QN and 
QD, can pfcrt polymorphisms influence transport of the aforementioned drugs?  
 
Uptake with fixed and varying concentrations of CQ, QN and QD showed some differences in 
transport with reference to the PfCRT alleles used. Amongst the mutant PfCRT variants 
tested, Dd2 and GB4 were found to transport QN and QD, whereas Ecu1110, 7G8, Ph1 and 
Ph2 showed uptake similar to that in controls (Fig 3.14). Verapamil-sensitive uptake of CQ 
was observed for all the mutant alleles (Fig 3.11). Expression of the sensitive HB3 allele did 
not lead to uptake for either of the drugs tested. As the only difference between the mutant 
alleles was in the polymorphisms they carried, this suggested that polymorphisms within 
PfCRT can influence substrate specificity to quinoline compounds. If so, how do they 
influence drug transport within the parasite? Genetically altered parasites carrying pfcrt alleles 
Dd2 and 7G8 in the same genetic background show decreased accumulation of CQ and QN as 
compared to parasites carrying wild type pfcrt (Sanchez et al., 2008b, Sanchez et al., 2005). In 
the same studies, however, parasites harbouring wild-type pfcrt too showed CQ efflux from 
the vacuole, although the kinetics of such an efflux were different compared to parasites with 
mutant pfcrt. Then why does the wild-type HB3 allele not exhibit uptake for CQ, QN and QD 
when expressed in oocytes? And why does 7G8 show accumulation of CQ but not that for QN 
when expressed heterologously? A possible explanation is that alleles such as HB3 and 7G8 
do interact with CQ, QN and QD when expressed, but that the release of the substrate from 
the binding site is very poor and therefore the amount of substrate translocated across the 
oocyte plasma membrane is much below detection levels. P. falciparum parasites within their 
host are at a temperature of 37°C, whereas the transport assays shown here were performed at 
25°C. Since protein conformation is influenced by temperature, it may be that the 
conformation of those alleles, for whom no QN or QD transport was detected, is not optimal 
at the assay temperature. Another scenario is that QN transport within P. falciparum requires 
factors in addition to PfCRT which are absent in the oocytes system, and hence some alleles 
showed no uptake for QN or QD when expressed in oocytes. Supporting this hypothesis is a 
report describing that the genetic background of P. falciparum parasites in which mutant pfcrt 
is replaced does play a role in determining QN IC50 values (Valderramos et al., 2010). 
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Moreover, another report shows that QN response differs amongst parasites with different 
genetic backgrounds but same alleles of pfcrt and pfmdr1 (Mu et al., 2003). The absence of 
QN transport, however, does not rule out an interaction between the south-american and 
philippine alleles and QN/QD. This can be checked by measuring CQ accumulation in PfCRT 
expressing oocytes in the presence of QN and QD. An inhibition of CQ uptake, if observed, 
can then investigate in further detail by comparing inhibitions constants for different alleles.  
 
Kinetic parameters such as the apparent Michaelis-Menten constant Km, apparent maximum 
velocity Vmax and Vmax/Km were measured for CQ transport mediated by PfCRT variants. The 
definition of apparent Vmax and Vmax/Km values includes the amount of active carrier protein 
mediating substrate transport (Atkins, 2010). Data shown in this work indicate major 
differences in the CQ Vmax values for PfCRT alleles (Table-3). A Western blot (Fig 3.17) 
showed that the amount of PfCRT HB3 protein was higher than that for Dd2, but yet no net 
uptake of CQ was seen. The 7G8 allele showed a weaker signal for PfCRT expression than 
other alleles. Ph2 allele had apparently higher expression than Ph1, and yet uptake levels did 
not differ significantly between the two. Thus, a more accurate analysis of Vmax is not possible 
without carefully comparing the levels of expression of each allele in the oocyte plasma 
membrane. One way of achieving this is by tagging PfCRT protein with a C-terminal tag such 
as a Haemagluttinin tag or a GFP moiety, and then biotinylating surface proteins to isolate the 
plasma membrane fraction. Another option available is to prepare slices of oocytes fixed in a 
polymer, label the protein of interest with an antibody and use a fluorescent tagged secondary 
antibody to visualize the protein. There are instances where such methods have been used 
successfully to demonstrate plasma membrane expression of heterologous proteins in 
X. laevis oocytes (Rotmann et al., 2004, Martin et al., 2009b, Nessler et al., 2004). Such a 
procedure can be used to normalize Vmax with respect to expression levels of each protein.  
Km, in contrast to Vmax, is independent of the amount of active carrier protein involved in 
transport (Atkins, 2010). This allowed a direct evaluation of how pfcrt polymorphisms may 
determine CQ Km. Table-3 permitted a grouping of PfCRT variants on the basis of CQ Km – 
low (7G8, Ph2), medium (Ecu1110, Ph1, Dd2) and high (GB4). In other words, saturation of 
PfCRT mediated CQ transport would occur at much higher concentration with the GB4 than 
with the 7G8 allele. This can be of therapeutic significance - if one were to increase the 
dosage of CQ administered to patients infected with P. falciparum strains harbouring a 7G8-
like pfcrt it would result in an accumulation of CQ in the digestive vacuole as the pfcrt 
mediated CQ efflux process would be saturated, which in theory can lead to parasite killing. 
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However, one should be reminded that such a scenario is highly unlikely because of the small 
therapeutic window for CQ (Hoshen et al., 1998). It is also probable that different alleles may 
have the same turnover number and transport efficiency for CQ, despite of the differences in 
their Km values. Turnover number is the ratio of the Vmax to the amount of carrier protein and 
it indicates number of molecules transported per unit binding site. The ratio of the turnover 
number to the Km is the efficiency of the enzyme, or in this case the carrier (Atkins, 2010). 
Even if two enzymes vary in their Km and Vmax values for a substrate, their efficiency can be 
similar. Just as with Vmax and Vmax/Km, an accurate determination of the turnover number and 
the carrier efficiency relied on Vmax values normalized with respect to levels of expression of 
the alleles in question.  
 
Verapamil has been known as a chemosensitizer of CQR for many years (Henry et al., 2006). 
CQ uptake was hence measured with verapamil to test if pfcrt polymorphisms influenced 
verapamil inhibition of CQ uptake. Verapamil induced decrease in CQ uptake was much more 
pronounced for Dd2 and GB4 alleles, whereas in comparison to these two the effect was not 
as strong in the other alleles measured (Fig 3.11). Dd2S220A and Dd2S326D constructs were 
identical to Dd2 in their verapamil reversibility (Table-3.14A), and same was the observation 
between Dd2 and GB4. This suggests that mutations in TMD other than TMD no.1 are not 
related to verapamil inhibition, but that the TMD no.1 is a major determinant. This result was 
in agreement with previous observations that CQ IC50 of Dd2 strain decreased to CQS levels 
with verapamil, but only a slight reduction was observed with the 7G8 strain (Mehlotra et al., 
2001, Sidhu et al., 2002). In another study, Lehane & Kirk demonstrated a verapamil induced 
proton leak in CQR but not wild-type parasites, and explained that this suggests verapamil to 
be a substrate of mutant but not wild-type PfCRT (Lehane & Kirk, 2010). They too observed 
strain specific differences in the verapamil effect between asian/African and south-american 
CQR parasites. The data shown in Fig 3.11 confirm that mutations in pfcrt influence its 
interaction with verapamil. Initial transport data suggest that verapamil is a substrate of 
PfCRT and inhibition kinetics point to mixed inhibition. It could be hypothesized that M74I 
and N75E substitutions present in Dd2 allele enhance binding of verapamil to PfCRT, and 
hence either out compete or block interaction between CQ and PfCRT, thus leading to 
decrease in CQ uptake. Lack of these substitutions in the SVMNT or CVMNT type pfcrt 
alleles would then lead to a much less pronounced inhibition effect with verapamil.  
 
Discussion 
 86
4.3 Role of single amino acid substitutions in PfCRT 
mediated transport 
 
Looking at the CQ uptake with different pfcrt alleles, it is evident that different combinations 
of amino acid substitutions can account for transport (Table-2, Fig 3.9). For instance Dd2 and 
Ph1 alleles have only the K76T substitution in common, whereas arginine at position 326 gets 
replaced with an aspartate in Ph1 and serine in Dd2. Ecu1110, on the other hand, harbours 
four substitutions as compared to wild-type, and each of these positions is also mutated in the 
Dd2 allele. And yet oocytes injected with all three accumulated significantly more CQ than 
the controls (Fig 3.9). While K76T alone does not account for CQ transport in oocytes, 
introducing T76K into the Dd2 background abrogates uptake (Martin et al., 2009b). Thus, 
more than one mutation has to be present in the wild-type to account for CQ transport, but 
different combinations of such mutations are possible. What then is the minimum number of 
substitutions required by wild-type PfCRT to transport CQ in oocytes? Measuring CQ 
transport with Ecu1110 back-mutants answered this question (Table-4, Fig 3.12). PfCRT with 
only three amino acid substitutions, namely K76T, D326N and L356I, can still mediate CQ 
uptake. That D326N is required was an interesting observation, because the position 32, along 
with 76 and 220, is found to be mutated in a majority of mutant CQ alleles identified from 
field isolates of P.falciparum (Cooper et al., 2005). But in contrast to K76T and D326N, 
S220A was expendable as Ecu1110S220A did not differ from Ecu1110 in its CQ uptake (Fig 
3.13). This was confirmed with Dd2S220A which too did not differ from Dd2 in its CQ uptake 
and verapamil reversibility (Fig 3.14A). QN and QD uptake between Dd2 and Dd2S220A was 
also similar (Fig 3.14B).  
 
GB4 and Dd2S326D alleles allowed a more detailed examination of position 326 and its role in 
quinoline transport. Ecu1110 mutants suggested that N236D is required for CQ uptake, GB4 
has no mutation at this position and retains the arginine residue found in wild-type PfCRT 
(Table-2), and yet GB4 expression in oocytes caused uptake of CQ, QN and QD. Dd2S326D 
mutant, on the other hand, had significantly decreased accumulation and Km for CQ than Dd2 
and did not cause uptake of QN and QD (Fig 3.15, Fig 3.16, and Table-5). Screening Ecu1110 
mutants CQ uptake showed that introducing D326N significantly reduced CQ accumulation 
(Fig-3.13). These constructs show that the amino acid present at position 326 may play a role 
in the substrate selectivity of PfCRT, as serine and arginine appear to favour QN/QD 
transport as compared to aspartate. This may explain why Ecu1110, 7G8, Ph1 and Ph2 PfCRT 
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were negative for QN and QD uptake, as they all have an aspartate as the 326th amino acid 
residue (Table-2). PfCRT GB4 also showed higher uptake for QD than its steroisomer QN 
(Fig 3.4), thus adding weight to the argument that position 326 plays an important role in 
quinoline transport by PfCRT. Thus, differential respsonses of PfCRT allele to CQ, QN and 
QD uptake may be in part explained by the residue occurring at position 326. 
 
Another variant residue is located at position 72 in PfCRT, which is either a cysteine or serine 
depending on the allele, with Ecu1110-7G8 and Ph1-Ph2 alleles differing only in this one 
respect. CQ IC50 values measured with C8Ph1 and C10Ph2 allelic exchange P. falciparum 
parasites yielded CQS-like CQ IC50 for Ph1 as against C10Ph2 which gave higher or CQR-
like IC50 values. An analysis of parasite fitness revealed C8Ph1 to be fitter than C10Ph2, and 
7G8 to be fitter than Dd2 (Dr. Ines Petersen, personal communication). However, CQ Km 
values were significantly different between Ph1-Ph2 and Ph2-7G8, but not between Ecu1110-
7G8. This suggests that while S72 implies a lower Km for CQ as compared C72, the effect of 
this substitution is not independent of other mutant residues.  
 
Other authors in the past have pointed out that distinct residues in PfCRT have a bearing on 
substrate specificity. Cooper et al. exposed P. falciparum106/1 strain to in vitro CQ pressured 
which yielded 106/1K76N and 106/1K76I strains having mutations at position 76 in pfcrt 
(Cooper et al., 2002). Of these the 106/1K76I was a CQ resistant line showing increased 
sensitivity to QN but reduced sensitivity to QD. In a separate study the authors exposed 
106/1K76I parasites to QN selection pressured, which gave parasites with additional pfcrt 
mutations (Cooper et al., 2007). These were 106/176I-352K, 106/176I-352R and 106/172R-76I, which 
were CQ sensitive but QN resistant. The authors argued that these mutations occur in TMD 1, 
4 and 9 of PfCRT which are often involved in substrate binding site in carriers of the drug-
metabolite transporter superfamily, of which PfCRT is thought to be a member (Martin & 
Kirk, 2004). Position 326 did not feature in these reports and to this day no other study 
showing effects of individual or pairs of mutations on substrate selectivity is known to have 
been published. Such a lack of overlap between this work and the studies by Cooper et al. is 
hardly suprising. The analyses involving oocyte expression of pfcrt alleles relied on mutations 
occuring in the field, where selection landscape involves many other parameters such as 
frequency of malaria transmission, host-parasite interactions, pharmacological properties of 
the drug to name a few (Mackinnon & Marsh, 2010).  
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The finding that the S220A mutation is not required for transport of CQ, QN or QD was 
hardly surprising. Mutations are selected under drug pressure not only to acquire the drug 
resistance phenotype, but also to balance the fitness cost incurred by introduction of such 
changes (Brown et al., 2010). Drug resistant P. falciparum strains are known to differ in their 
fitness as compared to the wild-type, as mutations in pfmdr1 gene and its amplification in 
multi-drug resistant P. falciparum has shown to contribute to decreased parasite fitness 
(Hayward et al., 2005, Preechapornkul et al., 2009). As for CQR parasites, discontinuation of 
CQ use in Malawi led to re-emergence of CQS malaria in Malawi (Kublin et al., 2003), which 
has been explained by re-emergence of CQS parasites under the lack of drug pressure (Laufer 
et al., 2010). These reports, along with reports showing seasonal carriage of CQR parasites in 
malaria-endemic regions (Ord et al., 2007) suggest that CQR parasites have decreased fitness. 
Within this context, it is not fanciful to hypothesize that the S220A mutation may be a 
compensatory mutation linked to parasite fitness, and hence its almost ubiquitous presence in 
CQR pfcrt (Cooper et al., 2005).  
 
 
4.4 Relationship between pfcrt, quinoline transport and 
drug resistant malaria 
 
The relationship between pfcrt polymorphisms, geography of the corresponding P. falciparum 
isolate and transport of CQ, QN and QD was examined earlier. But it is also possible to view 
the substrate specificity of PfCRT for aminoquinolines in the context of drug resistance or 
reduced susceptibility to these drugs, as observed in the field. Resistance to CQ is widespread 
across the world, and malaria endemic regions in South-America, Sub-saharan Africa as well 
as in South-East Asia carry CQR parasite strains (WHO, 2005). The Brazilian Amazon region 
is malaria endemic, and one study found that 97% of samples collected in this region to be 
resistant to CQ, as against 3% to QN (Cerutti Junior et al., 1999). Another study found that in 
isolates pertaining to patients coming from this region, 100% of the isolates tested were CQ 
resistant whereas 11% QN resistant (Segurado et al., 1997). In Africa, all countries except 
Djibouti and Swaziland show clinical treatment rate of failure to be higher than 25% for CQ. 
The same was around 80% in South-America and around 40% in South-East Asia in the year 
2002 (WHO, 2005). Quinine efficacy, on the other hand, was not as starkly reduced in South-
America, Africa or South-East Asia and observed failure rates with QN treatment remained 
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beween 5-10% (WHO, 2005). Each naturally occurring pfcrt allele tested positive for CQ 
transport in the oocyte assay, and this fits together with the observed pattern of CQR malaria 
as a mutant PfCRT transporting CQ out of the DV vacuole is consistent with CQR. However, 
a similar relationship cannot be established for QN transport and QN resistance. QN 
resistance is difficult to demonstrate as only low levels of QN resistance are observed across 
the world (WHO, 2005). Secondly, the South-American alleles which tested negative for QN 
transport in the oocyte assay, come from a region where reduced QN IC50 values for field 
isolates have been reported (Cerutti Junior et al., 1999). That QN is effective against CQ and 
mefloquine resistant P. falciparum supports such a lack of overlap between observed patterns 
of CQ and QN resistance. A QTL analysis of progenies from P. falciparum HB3 x Dd2 
crosses has shown in the past that 95% of CQR phenotype could be ascribed to a 
chromosomal section containing pfcrt, whereas the same QTL showed QN resistance to be a 
multifactorial trait (Ferdig et al., 2004). In order to better understand the influence of pfcrt 
alone on QN IC50, one could look at allelic exchange parasites that have the same genetic 
background and differ only in their pfcrt alleles. QN IC50 values measured for such parasites, 
namely C2GC03, C4Dd2 and C67G8, were measured to be 171, 93 and 71.5 nM respectively 
(Sidhu et al., 2002). Thus, QN IC50 values were not drastically different for parasites carrying 
Dd2 or 7G8 pfcrt. This suggests that QN IC50 and transport could be influenced by different 
factors within the parasite. So while PfCRT could transport both CQ and QN out of the DV, 
there may be factors within the parasite that influence QN but not CQ IC50. It is also tempting 
to speculate that the different mutant pfcrt polymorphisms may have been selected under 
different drug pressure conditions, such that alleles in one area would have got selected to 
transport a certain range of compounds that were being used, and in another area another 
allele got selected to transport say only CQ. There may also be a trade off between parasite 
fitness and the range of substrates being transporter by a particular pfcrt allele. This, however, 
remains to be experimentally examined.  
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5.  Outlook 
 
The work presented here argues in favour of PfCRT being a carrier for multiple substrates, and 
that polymorphisms in this protein influence its transport properties for such substrates. It 
however, also raises some questions that could not be answered within the scope of this study. 
Apart from chloroquine (CQ), quinine (QN) and quinidine (QD), uptake screens may be 
performed with more substrates such as verapamil, amodiaquine and lumenfantrine to name a 
few. It remains to be seen if quinolines share a binding site in PfCRT or interact with distinct 
sites, which can be ascertained by competition studies where transport of one substrate is 
measured in the presence of another. The measurement of plasma membrane expression levels 
for different constructs should offer further insights into the kinetics of PfCRT mediated CQ 
transport by allowing a determination of the turnover number and transport efficiency. Similar 
to CQ uptake, it needs to be ascertained as to which are the minimum number of changes 
required to transport QN, and whether compounds such as amodiaquine too get transported by 
such minimal constructs. The role of K76T substitution in PfCRT mediated transport needs to 
be further examined by replacing the threonine residues to see if other presence of other amino 
acid residues too can account for quinoline transport. Experiments outlined above can all be 
carried out in the Xenopus laevis expression system. Having the knowledge obtained from 
oocyte experiments, Plasmodium falciparum parasites could be engineered such that the 
endogenous pfcrt gets replaced with the construct of interest. This would allow a better 
understanding of the crucial role this trans-membrane protein plays in both parasite physiology 
and in conferring drug resistance.  
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pSP64T-PfCRT 
4551 bp
SP6 Promotor - 1
ßGlobin 5' UTR - 20
XhoI - 81 - C'TCGA_G
AvrII - 1374 - C'CTAG_G
NcoI - 1383 - C'CATG_G
ß Globin 3' UTR - 1394
PolyA - 1535
PstI - 1590 - C_TGCA'G
BamHI - 1604 - G'GATC_C
XmaI - 1609 - C'CCGG_G
SacI - 1620 - G_AGCT'C
EcoRI - 1622 - G'AATT_C
A
m
picill in  R
esistance
PfCRT
 
Vector map of PfCRT cloned into the pSP64T vector 
 
 
PfCRT HB3 sequence (MAL7P1.27)  
 
1    ATGAAGTTCG CCTCTAAGAA GAACAATCAA AAGAACTCCT CCAAGAATGC   
51   TGAAAGAGCT AGAGCTGCTG ATAATGCTGC TCAAGAAGGT AACGGTTCTA   
101  GATTGGGTGG TGGTTCTTGT TTGGGTAAAT GTGCTCATGC TGCTAAAGCT   
151  GCCTTCAAAG AAATCAAGGA CAACATCTTC ATCTACATCT TGTCCATCAT   
201  CTACTTGTCT GTTTGCGTCA TGAACAAGAT TTTCGCCAAG AGAACCTTGA   
251  ACAAGATTGG TAACTACTCT TTCGTTACCT CTGAAACCCA TAACTTCATC   
301  TGCATGATCA TGTTCTTCAT CGTCTATTCC TTGTTCGGTA ACAAGAAGGG   
351  TAACTCCAAA GAAAGACACA GATCCTTCAA CTTGCAATTC TTCGCCATTT   
401  CTATGTTGGA TGCCTGCTCT GTTATTTTGG CTTTCATCGG TTTGACTAGA   
451  ACTACCGGTA ACATCCAATC TTTCGTCTTG CAATTGTCCA TTCCAATCAA   
501  TATGTTCTTC TGCTTCTTGA TCTTGAGATA CAGATACCAC TTGTACAATT   
551  ACTTGGGTGC CGTTATTATT GTCGTTACCA TTGCCTTGGT TGAAATGAAG   
601  TTGTCCTTCG AAACCCAAGA AGAAAACTCC ATCATCTTCA ACTTGGTTTT   
651  GATTTCCGCC TTGATTCCAG TTTGTTTCTC CAACATGACC AGAGAAATCG   
701  TTTTCAAGAA GTACAAGATC GACATCTTGA GATTGAACGC TATGGTTTCC   
751  TTCTTCCAAT TATTCACCTC CTGCTTGATT TTGCCAGTTT ACACCTTGCC   
801  ATTCTTGAAG CAATTGCACT TGCCATACAA CGAAATTTGG ACCAACATCA   
851  AGAATGGTTT CGCTTGTTTG TTCTTGGGTA GAAACACCGT TGTTGAAAAC   
901  TGTGGTTTGG GTATGGCTAA GTTGTGTGAT GATTGTGATG GTGCTTGGAA   
951  AACTTTCGCT TTGTTCTCCT TCTTCAACAT CTGCGATAAC TTGATTACCT   
1001 CCTACATCAT CGATAAGTTC TCTACTATGA CCTACACCAT CGTTTCTTGT   
1051 ATTCAAGGTC CAGCTATTGC TATTGCCTAC TACTTCAAGT TTTTGGCCGG   
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1101 TGATGTTGTT AGAGAACCTA GATTATTGGA CTTCGTCACC TTGTTTGGTT   
1151 ACTTGTTCGG TTCCATTATC TACAGAGTCG GTAACATCAT CTTGGAAAGA   
1201 AAGAAGATGA GAAACGAAGA AAACGCTGAT TCTGCTGGTG CTTTGACTAA   
1251 TGTTGATTCT GCTGCTACTC AACCTAGGTA A  
 
1   MKFASKKNNQ KNSSKNAERA RAADNAAQEG NGSRLGGGSC LGKCAHAAKA   
51  AFKEIKDNIF IYILSIIYLS VCVMNKIFAK RTLNKIGNYS FVTSETHNFI   
101 CMIMFFIVYS LFGNKKGNSK ERHRSFNLQF FAISMLDACS VILAFIGLTR   
151 TTGNIQSFVL QLSIPINMFF CFLILRYRYH LYNYLGAVII VVTIALVEMK   
201 LSFETQEENS IIFNLVLISA LIPVCFSNMT REIVFKKYKI DILRLNAMVS   
251 FFQLFTSCLI LPVYTLPFLK QLHLPYNEIW TNIKNGFACL FLGRNTVVEN   
301 CGLGMAKLCD DCDGAWKTFA LFSFFNICDN LITSYIIDKF STMTYTIVSC   
351 IQGPAIAIAY YFKFLAGDVV REPRLLDFVT LFGYLFGSII YRVGNIILER   
401 KKMRNEENAD SAGALTNVDS AATQPR*  
 
 
PfCRT Dd2 sequence  
 
1    ATGAAGTTCG CCTCTAAGAA GAACAATCAA AAGAACTCCT CCAAGAATGC   
51   TGAAAGAGCT AGAGCTGCTG ATAATGCTGC TCAAGAAGGT AACGGTTCTA   
101  GATTGGGTGG TGGTTCTTGT TTGGGTAAAT GTGCTCATGC TGCTAAAGCT   
151  GCCTTCAAAG AAATCAAGGA CAACATCTTC ATCTACATCT TGTCCATCAT   
201  CTACTTGTCC GTTTGCGTTA TTGAAACCAT CTTCGCCAAG AGAACCTTGA   
251  ACAAGATTGG TAACTACTCT TTCGTTACCT CTGAAACCCA TAACTTCATC   
301  TGCATGATCA TGTTCTTCAT CGTCTATTCC TTGTTCGGTA ACAAGAAGGG   
351  TAACTCCAAA GAAAGACACA GATCCTTCAA CTTGCAATTC TTCGCCATTT   
401  CTATGTTGGA TGCCTGCTCT GTTATTTTGG CTTTCATCGG TTTGACTAGA   
451  ACTACCGGTA ACATCCAATC TTTCGTCTTG CAATTGTCCA TTCCAATCAA   
501  TATGTTCTTC TGCTTCTTGA TCTTGAGATA CAGATACCAC TTGTACAATT   
551  ACTTGGGTGC CGTTATTATT GTCGTTACCA TTGCCTTGGT TGAAATGAAG   
601  TTGTCCTTCG AAACCCAAGA AGAAAACTCC ATCATCTTCA ACTTGGTTTT   
651  GATCTCCTCA TTGATCCCAG TTTGTTTCTC TAACATGACC AGAGAAATCG   
701  TTTTCAAGAA GTACAAGATC GACATCTTGA GATTGAACGC TATGGTTTCC   
751  TTCTTCCAAT TATTCACCTC CTGCTTGATT TTGCCAGTTT ACACCTTGCC   
801  ATTCTTGAAA GAATTGCACT TGCCATACAA CGAAATTTGG ACCAACATCA   
851  AGAATGGTTT CGCTTGTTTG TTCTTGGGTA GAAACACCGT TGTTGAAAAC   
901  TGTGGTTTGG GTATGGCTAA GTTGTGTGAT GATTGTGATG GTGCTTGGAA   
951  AACTTTCGCT TTGTTCTCCT TCTTCTCCAT TTGCGATAAC TTGATCACCT   
1001 CCTACATTAT CGATAAGTTC TCCACTATGA CCTACACTAT CGTATCTTGC   
1051 ATTCAAGGTC CAGCTACTGC TATTGCTTAC TACTTCAAGT TCTTGGCTGG   
1101 TGATGTTGTT ATTGAACCTA GATTATTGGA CTTCGTCACC TTGTTTGGTT   
1151 ACTTGTTCGG TTCCATTATC TACAGAGTCG GTAACATCAT CTTGGAAAGA   
1201 AAGAAGATGA GAAACGAAGA AAACGCTGAT TCTGCTGGTG CTTTGACTAA   
1251 TGTTGATTCT GCTGCTACTC AACCTAGGTA A 
 
1   MKFASKKNNQ KNSSKNAERA RAADNAAQEG NGSRLGGGSC LGKCAHAAKA   
51  AFKEIKDNIF IYILSIIYLS VCVIETIFAK RTLNKIGNYS FVTSETHNFI   
101 CMIMFFIVYS LFGNKKGNSK ERHRSFNLQF FAISMLDACS VILAFIGLTR   
151 TTGNIQSFVL QLSIPINMFF CFLILRYRYH LYNYLGAVII VVTIALVEMK   
201 LSFETQEENS IIFNLVLISS LIPVCFSNMT REIVFKKYKI DILRLNAMVS   
251 FFQLFTSCLI LPVYTLPFLK ELHLPYNEIW TNIKNGFACL FLGRNTVVEN   
301 CGLGMAKLCD DCDGAWKTFA LFSFFSICDN LITSYIIDKF STMTYTIVSC   
351 IQGPATAIAY YFKFLAGDVV IEPRLLDFVT LFGYLFGSII YRVGNIILER   
401 KKMRNEENAD SAGALTNVDS AATQPR*  
 
 
 
 
 
Appendix 
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PfCRT GB4 sequence  
 
1    ATGAAGTTCG CCTCTAAGAA GAACAATCAA AAGAACTCCT CCAAGAATGC   
51   TGAAAGAGCT AGAGCTGCTG ATAATGCTGC TCAAGAAGGT AACGGTTCTA   
101  GATTGGGTGG TGGTTCTTGT TTGGGTAAAT GTGCTCATGC TGCTAAAGCT   
151  GCCTTCAAAG AAATCAAGGA CAACATCTTC ATCTACATCT TGTCCATCAT   
201  CTACTTGTCC GTTTGCGTTA TTGAAACCAT CTTCGCCAAG AGAACCTTGA   
251  ACAAGATTGG TAACTACTCT TTCGTTACCT CTGAAACCCA TAACTTCATC   
301  TGCATGATCA TGTTCTTCAT CGTCTATTCC TTGTTCGGTA ACAAGAAGGG   
351  TAACTCCAAA GAAAGACACA GATCCTTCAA CTTGCAATTC TTCGCCATTT   
401  CTATGTTGGA TGCCTGCTCT GTTATTTTGG CTTTCATCGG TTTGACTAGA   
451  ACTACCGGTA ACATCCAATC TTTCGTCTTG CAATTGTCCA TTCCAATCAA   
501  TATGTTCTTC TGCTTCTTGA TCTTGAGATA CAGATACCAC TTGTACAATT   
551  ACTTGGGTGC CGTTATTATT GTCGTTACCA TTGCCTTGGT TGAAATGAAG   
601  TTGTCCTTCG AAACCCAAGA AGAAAACTCC ATCATCTTCA ACTTGGTTTT   
651  GATCTCCTCA TTGATCCCAG TTTGTTTCTC TAACATGACC AGAGAAATCG   
701  TTTTCAAGAA GTACAAGATC GACATCTTGA GATTGAACGC TATGGTTTCC   
751  TTCTTCCAAT TATTCACCTC CTGCTTGATT TTGCCAGTTT ACACCTTGCC   
801  ATTCTTGAAA GAATTGCACT TGCCATACAA CGAAATTTGG ACCAACATCA   
851  AGAATGGTTT CGCTTGTTTG TTCTTGGGTA GAAACACCGT TGTTGAAAAC   
901  TGTGGTTTGG GTATGGCTAA GTTGTGTGAT GATTGTGATG GTGCTTGGAA   
951  AACTTTCGCT TTGTTCTCCT TCTTCAACAT CTGCGATAAC TTGATCACCT   
1001 CCTACATTAT CGATAAGTTC TCCACTATGA CCTACACTAT CGTATCTTGC   
1051 ATTCAAGGTC CAGCTATTGC TATTGCCTAC TACTTCAAGT TCTTGGCTGG   
1101 TGATGTTGTT ATTGAACCTA GATTATTGGA CTTCGTCACC TTGTTTGGTT   
1151 ACTTGTTCGG TTCCATTATC TACAGAGTCG GTAACATCAT CTTGGAAAGA   
1201 AAGAAGATGA GAAACGAAGA AAACGCTGAT TCTGCTGGTG CTTTGACTAA   
1251 TGTTGATTCT GCTGCTACTC AACCTAGGTA A 
 
1   MKFASKKNNQ KNSSKNAERA RAADNAAQEG NGSRLGGGSC LGKCAHAAKA   
51  AFKEIKDNIF IYILSIIYLS VCVIETIFAK RTLNKIGNYS FVTSETHNFI   
101 CMIMFFIVYS LFGNKKGNSK ERHRSFNLQF FAISMLDACS VILAFIGLTR   
151 TTGNIQSFVL QLSIPINMFF CFLILRYRYH LYNYLGAVII VVTIALVEMK   
201 LSFETQEENS IIFNLVLISS LIPVCFSNMT REIVFKKYKI DILRLNAMVS   
251 FFQLFTSCLI LPVYTLPFLK ELHLPYNEIW TNIKNGFACL FLGRNTVVEN   
301 CGLGMAKLCD DCDGAWKTFA LFSFFNICDN LITSYIIDKF STMTYTIVSC   
351 IQGPAIAIAY YFKFLAGDVV IEPRLLDFVT LFGYLFGSII YRVGNIILER   
401 KKMRNEENAD SAGALTNVDS AATQPR*  
 
 
PfCRT Ecu1110 sequence 
1    ATGAAGTTCG CCTCTAAGAA GAACAATCAA AAGAACTCCT CCAAGAATGC   
51   TGAAAGAGCT AGAGCTGCTG ATAATGCTGC TCAAGAAGGT AACGGTTCTA   
101  GATTGGGTGG TGGTTCTTGT TTGGGTAAAT GTGCTCATGC TGCTAAAGCT   
151  GCCTTCAAAG AAATCAAGGA CAACATCTTC ATCTACATCT TGTCCATCAT   
201  CTACTTGTCC GTTTGCGTCA TGAACACGAT TTTCGCCAAG AGAACCTTGA   
251  ACAAGATTGG TAACTACTCT TTCGTTACCT CTGAAACCCA TAACTTCATC   
301  TGCATGATCA TGTTCTTCAT CGTCTATTCC TTGTTCGGTA ACAAGAAGGG   
351  TAACTCCAAA GAAAGACACA GATCCTTCAA CTTGCAATTC TTCGCCATTT   
401  CTATGTTGGA TGCCTGCTCT GTTATTTTGG CTTTCATCGG TTTGACTAGA   
451  ACTACCGGTA ACATCCAATC TTTCGTCTTG CAATTGTCCA TTCCAATCAA   
501  TATGTTCTTC TGCTTCTTGA TCTTGAGATA CAGATACCAC TTGTACAATT   
551  ACTTGGGTGC CGTTATTATT GTCGTTACCA TTGCCTTGGT TGAAATGAAG   
601  TTGTCCTTCG AAACCCAAGA AGAAAACTCC ATCATCTTCA ACTTGGTTTT   
651  GATTTCCTCA TTGATTCCAG TTTGTTTCTC CAACATGACC AGAGAAATCG   
701  TTTTCAAGAA GTACAAGATC GACATCTTGA GATTGAACGC TATGGTTTCC   
751  TTCTTCCAAT TATTCACCTC CTGCTTGATT TTGCCAGTTT ACACCTTGCC   
801  ATTCTTGAAG CAATTGCACT TGCCATACAA CGAAATTTGG ACCAACATCA   
851  AGAATGGTTT CGCTTGTTTG TTCTTGGGTA GAAACACCGT TGTTGAAAAC   
901  TGTGGTTTGG GTATGGCTAA GTTGTGTGAT GATTGTGATG GTGCTTGGAA   
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951  AACTTTCGCT TTGTTCTCCT TCTTCGACAT CTGCGATAAC TTGATTACCT   
1001 CCTACATCAT CGATAAGTTC TCTACTATGA CCTACACCAT CGTTTCTTGT   
1051 ATTCAAGGTC CAGCTCTTGC TATTGCCTAC TACTTCAAGT TTTTGGCCGG   
1101 TGATGTTGTT AGAGAACCTA GATTATTGGA CTTCGTCACC TTGTTTGGTT   
1151 ACTTGTTCGG TTCCATTATC TACAGAGTCG GTAACATCAT CTTGGAAAGA   
1201 AAGAAGATGA GAAACGAAGA AAACGCTGAT TCTGCTGGTG CTTTGACTAA   
1251 TGTTGATTCT GCTGCTACTC AACCTAGGTA A 
 
1   MKFASKKNNQ KNSSKNAERA RAADNAAQEG NGSRLGGGSC LGKCAHAAKA   
51  AFKEIKDNIF IYILSIIYLS VCVMNTIFAK RTLNKIGNYS FVTSETHNFI   
101 CMIMFFIVYS LFGNKKGNSK ERHRSFNLQF FAISMLDACS VILAFIGLTR   
151 TTGNIQSFVL QLSIPINMFF CFLILRYRYH LYNYLGAVII VVTIALVEMK   
201 LSFETQEENS IIFNLVLISS LIPVCFSNMT REIVFKKYKI DILRLNAMVS   
251 FFQLFTSCLI LPVYTLPFLK QLHLPYNEIW TNIKNGFACL FLGRNTVVEN   
301 CGLGMAKLCD DCDGAWKTFA LFSFFDICDN LITSYIIDKF STMTYTIVSC   
351 IQGPALAIAY YFKFLAGDVV REPRLLDFVT LFGYLFGSII YRVGNIILER   
401 KKMRNEENAD SAGALTNVDS AATQPR*  
 
 
PfCRT 7G8 sequence 
1    ATGAAGTTCG CCTCTAAGAA GAACAATCAA AAGAACTCCT CCAAGAATGC   
51   TGAAAGAGCT AGAGCTGCTG ATAATGCTGC TCAAGAAGGT AACGGTTCTA   
101  GATTGGGTGG TGGTTCTTGT TTGGGTAAAT GTGCTCATGC TGCTAAAGCT   
151  GCCTTCAAAG AAATCAAGGA CAACATCTTC ATCTACATCT TGTCCATCAT   
201  CTACTTGTCT GTTAGCGTCA TGAACACGAT TTTCGCCAAG AGAACCTTGA   
251  ACAAGATTGG TAACTACTCT TTCGTTACCT CTGAAACCCA TAACTTCATC   
301  TGCATGATCA TGTTCTTCAT CGTCTATTCC TTGTTCGGTA ACAAGAAGGG   
351  TAACTCCAAA GAAAGACACA GATCCTTCAA CTTGCAATTC TTCGCCATTT   
401  CTATGTTGGA TGCCTGCTCT GTTATTTTGG CTTTCATCGG TTTGACTAGA   
451  ACTACCGGTA ACATCCAATC TTTCGTCTTG CAATTGTCCA TTCCAATCAA   
501  TATGTTCTTC TGCTTCTTGA TCTTGAGATA CAGATACCAC TTGTACAATT   
551  ACTTGGGTGC CGTTATTATT GTCGTTACCA TTGCCTTGGT TGAAATGAAG   
601  TTGTCCTTCG AAACCCAAGA AGAAAACTCC ATCATCTTCA ACTTGGTTTT   
651  GATTTCCTCA TTGATTCCAG TTTGTTTCTC CAACATGACC AGAGAAATCG   
701  TTTTCAAGAA GTACAAGATC GACATCTTGA GATTGAACGC TATGGTTTCC   
751  TTCTTCCAAT TATTCACCTC CTGCTTGATT TTGCCAGTTT ACACCTTGCC   
801  ATTCTTGAAG CAATTGCACT TGCCATACAA CGAAATTTGG ACCAACATCA   
851  AGAATGGTTT CGCTTGTTTG TTCTTGGGTA GAAACACCGT TGTTGAAAAC   
901  TGTGGTTTGG GTATGGCTAA GTTGTGTGAT GATTGTGATG GTGCTTGGAA   
951  AACTTTCGCT TTGTTCTCCT TCTTCGACAT CTGCGATAAC TTGATTACCT   
1001 CCTACATCAT CGATAAGTTC TCTACTATGA CCTACACCAT CGTTTCTTGT   
1051 ATTCAAGGTC CAGCTCTTGC TATTGCCTAC TACTTCAAGT TTTTGGCCGG   
1101 TGATGTTGTT AGAGAACCTA GATTATTGGA CTTCGTCACC TTGTTTGGTT   
1151 ACTTGTTCGG TTCCATTATC TACAGAGTCG GTAACATCAT CTTGGAAAGA   
1201 AAGAAGATGA GAAACGAAGA AAACGCTGAT TCTGCTGGTG CTTTGACTAA   
1251 TGTTGATTCT GCTGCTACTC AACCTAGGTA A  
 
1   MKFASKKNNQ KNSSKNAERA RAADNAAQEG NGSRLGGGSC LGKCAHAAKA   
51  AFKEIKDNIF IYILSIIYLS VSVMNTIFAK RTLNKIGNYS FVTSETHNFI   
101 CMIMFFIVYS LFGNKKGNSK ERHRSFNLQF FAISMLDACS VILAFIGLTR   
151 TTGNIQSFVL QLSIPINMFF CFLILRYRYH LYNYLGAVII VVTIALVEMK   
201 LSFETQEENS IIFNLVLISS LIPVCFSNMT REIVFKKYKI DILRLNAMVS   
251 FFQLFTSCLI LPVYTLPFLK QLHLPYNEIW TNIKNGFACL FLGRNTVVEN   
301 CGLGMAKLCD DCDGAWKTFA LFSFFDICDN LITSYIIDKF STMTYTIVSC   
351 IQGPALAIAY YFKFLAGDVV REPRLLDFVT LFGYLFGSII YRVGNIILER   
401 KKMRNEENAD SAGALTNVDS AATQPR*  
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PfCRT Ph1 sequence 
 
1    ATGAAGTTCG CCTCTAAGAA GAACAATCAA AAGAACTCCT CCAAGAATGC   
51   TGAAAGAGCT AGAGCTGCTG ATAATGCTGC TCAAGAAGGT AACGGTTCTA   
101  GATTGGGTGG TGGTTCTTGT TTGGGTAAAT GTGCTCATGC TGCTAAAGCT   
151  GCCTTCAAAG AAATCAAGGA CAACATCTTC ATCTACATCT TGTCCATCAT   
201  CTACTTGTCT GTTTGCGTCA TGAACACGAT TTTCGCCAAG AGAACCTTGA   
251  ACAAGATTGG TAACTACTCT TTCGTTACCT CTGAAACCCA TAACTTCATC   
301  TGCATGATCA TGTTCTTCAT CGTCTATTCC TTGTTCGGTA ACAAGAAGGG   
351  TAACTCCAAA GAAAGACACA GATCCTTCAA CTTGCAATTC TTCGCCATTT   
401  CTATGTTGGA TGCCTGCTCT GTTATTTTGA CTTTCATCGG TTTGACTAGA   
451  ACTACCGGTA ACATCCAATC TTTCGTCTAC CAATTGTCCA TTCCAATCAA   
501  TATGTTCTTC TGCTTCTTGA TCTTGAGATA CAGATACCAC TTGTACAATT   
551  ACTTGGGTGC CGTTATTATT GTCGTTACCA TTGCCTTGGT TGAAATGAAG   
601  TTGTCCTTCG AAACCCAAGA AGAAAACTCC ATCATCTTCA ACTTGGTTTT   
651  GATTTCCGCC TTGATTCCAG TTTGTTTCTC CAACATGACC AGAGAAATCG   
701  TTTTCAAGAA GTACAAGATC GACATCTTGA GATTGAACGC TATGGTTTCC   
751  TTCTTCCAAT TATTCACCTC CTGCTTGATT TTGCCAGTTT ACACCTTGCC   
801  ATTCTTGAAG CAATTGCACT TGCCATACAA CGAAATTTGG ACCAACATCA   
851  AGAATGGTTT CGCTTGTTTG TTCTTGGGTA GAAACACCGT TGTTGAAAAC   
901  TGTGGTTTGG GTATGGCTAA GTTGTGTGAT GATTGTGATG GTGCTTGGAA   
951  AACTTTCGCT TTGTTCTCCT TCTTCGACAT CTGCGATAAC TTGATTACCT   
1001 CCTACATCAT CGATAAGTTC TCTACTATGA CCTACACCAT CGTTTCTTGT   
1051 ATTCAAGGTC CAGCTATTGC TATTGCCTAC TACTTCAAGT TTTTGGCCGG   
1101 TGATGTTGTT AGAGAACCTA GATTATTGGA CTTCGTCACC TTGTTTGGTT   
1151 ACTTGTTCGG TTCCATTATC TACAGAGTCG GTAACATCAT CTTGGAAAGA   
1201 AAGAAGATGA GAAACGAAGA AAACGCTGAT TCTGCTGGTG CTTTGACTAA   
1251 TGTTGATTCT GCTGCTACTC AACCTAGGTA A  
 
1   MKFASKKNNQ KNSSKNAERA RAADNAAQEG NGSRLGGGSC LGKCAHAAKA   
51  AFKEIKDNIF IYILSIIYLS VCVMNTIFAK RTLNKIGNYS FVTSETHNFI   
101 CMIMFFIVYS LFGNKKGNSK ERHRSFNLQF FAISMLDACS VILTFIGLTR   
151 TTGNIQSFVY QLSIPINMFF CFLILRYRYH LYNYLGAVII VVTIALVEMK   
201 LSFETQEENS IIFNLVLISA LIPVCFSNMT REIVFKKYKI DILRLNAMVS   
251 FFQLFTSCLI LPVYTLPFLK QLHLPYNEIW TNIKNGFACL FLGRNTVVEN   
301 CGLGMAKLCD DCDGAWKTFA LFSFFDICDN LITSYIIDKF STMTYTIVSC   
351 IQGPAIAIAY YFKFLAGDVV REPRLLDFVT LFGYLFGSII YRVGNIILER   
401 KKMRNEENAD SAGALTNVDS AATQPR*  
 
 
PfCRT Ph2 sequences 
 
1    ATGAAGTTCG CCTCTAAGAA GAACAATCAA AAGAACTCCT CCAAGAATGC   
51   TGAAAGAGCT AGAGCTGCTG ATAATGCTGC TCAAGAAGGT AACGGTTCTA   
101  GATTGGGTGG TGGTTCTTGT TTGGGTAAAT GTGCTCATGC TGCTAAAGCT   
151  GCCTTCAAAG AAATCAAGGA CAACATCTTC ATCTACATCT TGTCCATCAT   
201  CTACTTGTCT GTTAGCGTCA TGAACACGAT TTTCGCCAAG AGAACCTTGA   
251  ACAAGATTGG TAACTACTCT TTCGTTACCT CTGAAACCCA TAACTTCATC   
301  TGCATGATCA TGTTCTTCAT CGTCTATTCC TTGTTCGGTA ACAAGAAGGG   
351  TAACTCCAAA GAAAGACACA GATCCTTCAA CTTGCAATTC TTCGCCATTT   
401  CTATGTTGGA TGCCTGCTCT GTTATTTTGA CTTTCATCGG TTTGACTAGA   
451  ACTACCGGTA ACATCCAATC TTTCGTCTAC CAATTGTCCA TTCCAATCAA   
501  TATGTTCTTC TGCTTCTTGA TCTTGAGATA CAGATACCAC TTGTACAATT   
551  ACTTGGGTGC CGTTATTATT GTCGTTACCA TTGCCTTGGT TGAAATGAAG   
601  TTGTCCTTCG AAACCCAAGA AGAAAACTCC ATCATCTTCA ACTTGGTTTT   
51  GATTTCCGCC TTGATTCCAG TTTGTTTCTC CAACATGACC AGAGAAATCG   
701  TTTTCAAGAA GTACAAGATC GACATCTTGA GATTGAACGC TATGGTTTCC   
751  TTCTTCCAAT TATTCACCTC CTGCTTGATT TTGCCAGTTT ACACCTTGCC   
801  ATTCTTGAAG CAATTGCACT TGCCATACAA CGAAATTTGG ACCAACATCA   
851  AGAATGGTTT CGCTTGTTTG TTCTTGGGTA GAAACACCGT TGTTGAAAAC   
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901  TGTGGTTTGG GTATGGCTAA GTTGTGTGAT GATTGTGATG GTGCTTGGAA   
951  AACTTTCGCT TTGTTCTCCT TCTTCGACAT CTGCGATAAC TTGATTACCT   
1001 CCTACATCAT CGATAAGTTC TCTACTATGA CCTACACCAT CGTTTCTTGT   
1051 ATTCAAGGTC CAGCTATTGC TATTGCCTAC TACTTCAAGT TTTTGGCCGG   
1101 TGATGTTGTT AGAGAACCTA GATTATTGGA CTTCGTCACC TTGTTTGGTT   
1151 ACTTGTTCGG TTCCATTATC TACAGAGTCG GTAACATCAT CTTGGAAAGA   
1201 AAGAAGATGA GAAACGAAGA AAACGCTGAT TCTGCTGGTG CTTTGACTAA   
1251 TGTTGATTCT GCTGCTACTC AACCTAGGTA A 
 
1   MKFASKKNNQ KNSSKNAERA RAADNAAQEG NGSRLGGGSC LGKCAHAAKA   
51  AFKEIKDNIF IYILSIIYLS VSVMNTIFAK RTLNKIGNYS FVTSETHNFI   
101 CMIMFFIVYS LFGNKKGNSK ERHRSFNLQF FAISMLDACS VILTFIGLTR   
151 TTGNIQSFVY QLSIPINMFF CFLILRYRYH LYNYLGAVII VVTIALVEMK   
201 LSFETQEENS IIFNLVLISA LIPVCFSNMT REIVFKKYKI DILRLNAMVS   
251 FFQLFTSCLI LPVYTLPFLK QLHLPYNEIW TNIKNGFACL FLGRNTVVEN   
301 CGLGMAKLCD DCDGAWKTFA LFSFFDICDN LITSYIIDKF STMTYTIVSC   
351 IQGPAIAIAY YFKFLAGDVV REPRLLDFVT LFGYLFGSII YRVGNIILER   
401 KKMRNEENAD SAGALTNVDS AATQPR*  
 
 
 
